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DISSERTATION ABSTRACT 
 
Brett Romano Ely  
 
Doctor of Philosophy 
 
Department of Human Physiology 
 
June 2018 
 
Title: Chronic Passive Heat Exposure and Cardiometabolic Health in Obese Women with 
Polycystic Ovary Syndrome 
 
Polycystic Ovary Syndrome (PCOS) is a complex endocrine disorder that increases 
a woman’s risk of developing cardiovascular disease and diabetes. Women with PCOS 
have extremely high rates of obesity, insulin resistance, cardiovascular morbidity and 
mortality. Obese women with PCOS also tend to have elevated sympathetic nerve 
activity and systemic markers of inflammation, which likely contribute to 
cardiometabolic risk and PCOS pathogenesis. While few medication or lifestyle 
intervention options for women with PCOS target elevated sympathetic nerve activity, 
inflammation, and insulin resistance, passive heat exposure shows promise as a novel 
intervention for improving cardiovascular and metabolic health in this population.  
Therefore, the purpose of this study was to examine changes in inflammation, 
cardiovascular, autonomic, and metabolic health in obese women with PCOS following a 
30-session, 8-10 week chronic passive heat intervention (termed ‘heat therapy’). Eighteen 
obese women with PCOS (Age: 27±1y, BMI 41.3±1.1 kg·m2) were matched for age and 
body mass index (BMI), then divided into heat therapy (HT) or time control (CON). At 
the beginning (Pre), middle (Mid), and end (Post) of 8-10 weeks, subjects participated in 
study days to assess vascular, autonomic, and metabolic function, and additionally 
underwent a subcutaneous fat biopsy in Pre and Post. HT subjects took part in 30 one-
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hour hot tub sessions over 8-10 weeks (3-4 per week) in 40.5˚C water, while CON 
subjects completed all other testing but were not exposed to heat. No change in BMI was 
observed over the study in HT or CON; however; HT subjects exhibited dramatically 
improved vascular and metabolic function, as well as reduced sympathetic nerve activity 
and circulating inflammatory markers. In fat biopsies, insulin signaling was improved in 
HT subjects, while CON subjects remained stable over time. These findings show 
promise for HT as a treatment option for obese women with PCOS to improve 
cardiovascular and metabolic risk profiles.  
This dissertation includes previously published co-authored material. 
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CHAPTER I 
INTRODUCTION 
 
Obesity and associated disease rates have reached epidemic proportions, with 
nearly two billion people worldwide being classified as overweight or obese (Swinburn et 
al., 2011). For example, as of 2012, 33.7% of men and 36.5% of women in the United 
States were classified as obese (BMI≥30) (Ogden et al., 2013), and 9.3% of the U.S. 
population suffered from type II diabetes, a disease closely associated with excess fat 
mass and a sedentary lifestyle. While all obese individuals are at an elevated risk of 
cardiometabolic dysfunction compared to healthy weight counterparts, there appears to 
be a sex difference, placing women with diabetes at an elevated risk for cardiovascular 
death as compared to obese, diabetic men (Huxley, 2006).  Within the population of 
obese women, diagnosis with polycystic ovary syndrome (PCOS) additionally carries a 
disproportionate risk of cardiovascular disease, diabetes, and cardiovascular death (Wild 
et al., 2010).  PCOS is a complex neuroendocrine disorder characterized by clinical 
hyperandrogenism, menstrual dysfunction, and presence of ovarian cysts with ultrasound 
examination (Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, 
2004). Depending on the diagnostic criteria used, between 5-18% of women of child-
bearing age have PCOS (Spritzer et al., 2015; Dunaif, 2017), and over 50% of women 
with PCOS are classified as obese (Gambineri et al., 2002). In addition to well-described 
weight and fertility issues, the metabolic, autonomic, and hormonal profiles in women 
with PCOS greatly increase the risk for obesity, insulin resistance, and cardiovascular 
disease (Luque-Ramírez & Escobar-Morreale, 2014).  Sympathetic over-activity 
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(Lansdown & Rees, 2012; Ribiero et al., 2016) and systemic, low-grade inflammation 
(termed ‘meta-inflammation’) (Shorakae et al., 2015) may underlie the pathogenesis of 
PCOS and additionally increase risk of cardiovascular disease and diabetes, so the 
potential impact of a lifestyle intervention aimed at improving cardiometabolic health 
through reducing inflammation and sympathetic outflow would be particularly promising 
in this population.  
Common pharmacological interventions in women with PCOS focus on managing 
the menstrual dysfunction (oral contraceptives), symptoms related to excess testosterone 
(oral contraceptives and/or Spironolactone), and insulin resistance (Metformin) that are 
hallmarks of the syndrome. While these medications are effective in reducing signs and 
symptoms of PCOS, including irregular menses, acne, and hirsutism, few have an impact 
on cardiovascular health, metabolic health, or weight management. Metformin can act as 
an insulin sensitizing agent while additionally reducing free androgen levels, but does not 
appear to enhance weight loss when combined with lifestyle interventions (Tang et al., 
2006). Oral contraceptives reduce menstrual dysfunction and androgen excess, but do not 
appear to improve cardiovascular risk (Orio et al., 2016) and may even exacerbate 
metabolic dysfunction in overweight/obese women with PCOS (Legro et al., 2015). 
Current lifestyle interventions for obese women with PCOS emphasize weight loss 
through dietary modification and exercise training. The most commonly reported health 
outcomes with exercise training interventions in PCOS are weight loss, improved insulin 
resistance, and improved ovulation (Harrison et al., 2011a), with some research also 
indicating improved autonomic function (Giallauria et al., 2008; Stener-Victorin et al., 
2009) and reduced systemic inflammation (Giallauria et al., 2008). While changing diet 
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and exercise patterns can be effective strategies for reducing body mass, improving 
health, and managing PCOS symptoms, compliance is often low in clinical populations 
(Burgess et al., 2017), with drop-out rates as high as 45% in some exercise intervention 
studies in PCOS (Harrison et al., 2011b). Chronic, passive heat exposure (termed ‘heat 
therapy’) may offer an alternative or supplemental therapy to improve metabolic health 
and provide protection from cardiovascular disease in obese women with PCOS. The 
background literature supporting this is reviewed in Chapter II, which includes previously 
published co-authored material (Ely et al., 2018). Previous work examining repeated heat 
exposure in humans has shown promising improvements in metabolic health (Hooper, 
1992; Hunter et al., 2013a), cardiovascular health (Hunter et al., 2013b; Brunt et al., 
2016b, 2016c), and risk of cardiovascular death (Laukkanen et al., 2015), although 
mechanisms are still being elucidated. From animal literature, there are a variety of 
potential mechanisms for the observed improvements in cardiovascular and metabolic 
health with heat therapy; however; heat therapy has never been examined as a lifestyle 
intervention or potential treatment for PCOS. 
The purpose of this dissertation is to highlight the cardiometabolic decline in 
obese women with PCOS stemming from sympathetic over-activity and meta-
inflammation, and to examine the ways in which a long-term (30 sessions over 8-10 
weeks) heat therapy intervention can intersect with this decline in function to improve or 
restore cardiovascular and metabolic health. Our primary targets of interest include 
vascular health, autonomic function, and metabolic health, all of which are impaired in 
obese women with PCOS and will potentially be impacted by heat therapy. More 
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specifically, we examined a 30-session (8-10 week) heat therapy intervention in obese 
women with PCOS through the following specific aims: 
 
Specific Aim 1 (Chapter IV). To examine changes in vascular function in response to 30 
sessions of heat therapy. This was assessed through measurement of carotid and femoral 
wall thickness, measures of arterial stiffness including dynamic arterial compliance and 
pulse wave velocity, and flow-mediated dilation (FMD) of the brachial artery before and 
after a brief ischemia-reperfusion stress. We hypothesized that heat therapy would reduce 
wall thickness, decrease arterial stiffness, improve FMD, and attenuate the decline in 
FMD observed in response to ischemia-reperfusion. 
 
Specific Aim 2 (Chapter V). To examine changes in autonomic function in response to 
30 sessions of heat therapy. This was accomplished by measuring baseline muscle 
sympathetic nerve activity (MSNA), heart rate variability, and blood pressure, and by 
examining MSNA and blood pressure responses to the Valsalva maneuver. We 
hypothesized that blood pressure would decrease by a clinically meaningful margin 
(≥3mmHg, as defined by the U.S. Food & Drug Administration), baseline MSNA burst 
incidence would be lower, but baroreflex sensitivity during the Valsalva maneuver would 
not change. In addition, we hypothesized that total heart rate variability would increase, 
and that frequency analysis would indicate increased high-frequency and decreased low-
frequency variability. 
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Specific Aim 3 (Chapter VI). To examine changes in inflammation, metabolic health 
and function in response to 30 sessions of heat therapy. This was done through a 75g, 2-
hour oral glucose tolerance test (OGTT) and subcutaneous adipose tissue biopsy. 
Additionally, markers related to insulin sensitivity (fasting glucose, serum adiponectin) 
and inflammation (IL-1β, IL-6, TNFα) were examined in fasting blood samples. We 
hypothesized that both glucose and insulin would be reduced at all time points in the 
OGTT, and that isolated adipocytes would display increased insulin sensitivity. In 
addition, we hypothesized that increases in HSPs, increased serum adiponectin, and 
reductions in adipose tissue and serum markers of inflammation would potentially drive 
these changes in metabolic health. 
 
If these specific aims are achieved and these hypotheses are supported, this research will 
be the first to provide thorough and compelling evidence that heat therapy can improve 
cardiometabolic health in obese women with PCOS, a population at high risk for 
cardiovascular and metabolic dysfunction. 
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CHAPTER II 
REVIEW OF LITERATURE 
 
This chapter includes previously published co-authored material (Ely et al., 
2018). Z.S. Clayton, C.E. McCurdy, J. Pfeiffer, and C.T. Minson provided editorial input. 
Reports of PCOS in medical literature range as far back as the fifth century, with 
Hippocrates documenting case reports of two amenorrhoeic, hirsute women from 
neighboring towns on the North Aegean sea (Hippocrates, 1734). This combination of 
menstrual dysfunction and androgen excess was first linked to metabolic disturbances in 
1921 by Archard and Thiers as “diabete des femmes a barb” (diabetes of bearded women) 
(Achard & Thiers, 1921).  Connecting this cluster of symptoms to the condition now 
known as PCOS, Stein and Leventhal, in 1935, published a case study of seven women 
with amenorrhea, symptoms related to androgen excess, obesity, and polycystic ovaries 
(Stein & Leventhal, 1935). Since that report, research exploring the causal link between 
androgen excess, reproductive dysfunction, insulin resistance, and obesity has further 
characterized the PCOS phenotype. In addition to the hallmark characteristics of this 
syndrome (androgen excess, amenorrhea, and polycystic ovaries), women with PCOS 
tend to have extremely high rates of obesity (>50%, as high as 80% reported) (Dunaif, 
2017), insulin resistance (75-95%) (Stepto et al., 2013), hypertension (20%) (Luque-
Ramírez et al., 2014), and an elevated risk of cardiovascular or cerebrovascular death 
(Dahlgren et al., 1992; Rizzo et al., 2009; de Groot et al., 2011). Evidence points to an 
increase in systemic inflammation (Shorakae et al., 2015) and sympathetic over-activity 
(Lansdown & Rees, 2012) as primary sources of both metabolic and cardiovascular 
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dysfunction in obese women with PCOS (Figure 1). The following sections will discuss 
the role of inflammation in insulin resistance and metabolic health, the contributions and 
interconnections between inflammation, insulin resistance, and sympathetic overactivity 
to cardiovascular disease and risk in obese women with PCOS. This chapter will then 
highlight the potential therapeutic role of a heat intervention in reducing inflammation, 
insulin resistance, and sympathetic activity in obese women with PCOS, and how those 
factors can reduce cardiometabolic risk.  Evidence from human work is included 
whenever possible; however, in this emerging area of research animal models are 
included in discussion of potential physiological underpinnings.  
 
 
 
Figure 1. PCOS is associated with a cluster of conditions that increase 
cardiometabolic risk, including androgen excess, obesity, insulin resistance, and 
sympathetic overactivity. The hormonal, autonomic, and metabolic complications in 
PCOS manifest as elevated blood pressure, arterial stiffness, endothelial dysfunction, 
inflammation, and an increased risk of cardiovascular or cerebrovascular death.  
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Inflammation and Insulin Resistance in Obesity and PCOS 
In women with PCOS, higher levels of inflammatory markers including C-
reactive protein, interleukin 6 (IL-6), and tumor necrosis factor α (TNFα) have been 
observed, even in the absence of obesity (Shorakae et al., 2015). These proteins may be 
secreted by adipose tissue, liver, and skeletal muscle, and have implications in both 
metabolic and cardiovascular dysfunction. The connection between obesity and 
inflammation was first clearly described in an animal model of obesity and diabetes. 
Hotamisligil (Hotamisligil et al., 2017) demonstrated that elevated systemic and adipose 
tissue TNFα  abundance were associated with impaired glucose tolerance and reduced 
adipocyte glucose uptake.  
The combination of early reports of elevated inflammation in obese, diabetic 
individuals (Nanji et al., 1985) and the finding that anti-inflammatory therapy 
(salicylates) reversed insulin resistance in obese rodents (Yuan et al., 2001) led to the 
current theory that inflammation drives obesity-induced insulin resistance. This theory is 
further expanded in PCOS, with contributions from hyperandrogenism and autonomic 
dysregulation contributing to obesity, inflammation, and insulin resistance. The 
pathophysiological link between obesity and metabolic disease relates to increased 
triglyceride storage in adipocytes, driven in part by androgen excess in women with 
PCOS promoting adipocyte hypertrophy over hyperplasia (Diamanti-Kandarakis et al., 
2007), causing adipose tissue hypoxia through compression of capillary networks and 
inadequate blood supply relative to cell size (Trayhurn et al., 2008; Ye, 2009). This 
initiates a cascade of adipocyte apoptosis, followed by a pro-inflammatory immune 
response (see figure 2). The immune response involves a variety of chemokines, 
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adipokines, and immune cells, which alter the profile of adipose tissue to a pro-
inflammatory phenotype (Osborn & Olefsky, 2012). The change in immune cell profile 
includes an increase in M1 macrophages forming a crown-like structure around the 
adipocyte (Cinti, 2005) and releasing pro-inflammatory cytokines in the adipose tissue. 
Adipocytes act in a synergistic paracrine fashion with resident macrophages to increase 
inflammatory cytokine release by the other tissue. These cytokines are thought to disrupt 
insulin signaling in adipose tissue through serine phosphorylation of the insulin receptor 
substrate (IRS), which blocks tyrosine binding sites needed to activate the IRS within the 
cell and allow insulin signaling to occur.   
Indeed, women with PCOS have disrupted insulin signaling in adipose tissue 
(Ciaraldi et al., 1997; Echiburú et al., 2018), resulting in impaired glucose uptake and 
incomplete suppression of free fatty acid release. The primary function of insulin in 
adipose tissue is suppression of triglyceride breakdown and fatty acid release into 
circulation, so the result of this impairment is increased fatty acids in the bloodstream 
(Zierath et al., 1998). Fatty acid release is additionally driven by serum catecholamine 
levels, which are elevated in PCOS due to sympathetic over-activity (Yoshino et al., 
1991). These circulating fatty acids can accumulate in the liver and skeletal muscle and 
produce fatty acid intermediates such as diacylglycerol, ceramides, and long-chain fatty 
acid-Acyl CoA (Koves et al., 2008), all of which can inhibit intracellular insulin 
signaling by activation of c-Jun NH2-terminal Kinase (JNK) (Nguyen et al., 2005) or 
Inhibitor of kappa B kinase β (IKKβ) (Yuan et al., 2001; Arkan et al., 2005). JNK and 
IKKβ similarly impair intracellular insulin signaling by serine phosphorylation of IRS 
(Yin et al., 1998). This results in systemic insulin resistance with an impaired ability of 
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cells to transport glucose or suppress glucose production, creating a hyperglycemic, 
hyperinsulinemic profile in PCOS (Burghen et al., 1980). Exercise training programs 
produce reliable improvements in insulin resistance, with concurrent reductions in 
inflammation in women with PCOS (Giallauria et al., 2008; Covington et al., 2016) and 
obese individuals without PCOS, when accompanied by weight loss (Nicoletti et al., 
2003), providing evidence that inflammation and obesity work in concert to drive insulin 
resistance in PCOS. 
In addition, adipokines such as leptin and adiponectin are altered in obese women 
with PCOS (Spritzer et al., 2015), with lower adiponectin secretion contributing to or 
exacerbating insulin resistance (Villa & Pratley, 2011). Adiponectin is positively 
correlated with insulin sensitivity (Díez & Iglesias, 2003), potentially acting by changing 
macrophage polarization toward an anti-inflammatory profile (Ohashi et al., 2010). The 
end result of adipose tissue impairment is a hyper-insulinemic and meta-inflammatory 
profile in obese women with PCOS that vastly increases the risk of developing both 
metabolic and cardiovascular disease (Facchini et al., 2001). The meta-inflammation in 
PCOS may be due in part to sympathetic nervous system dysregulation. In turn, 
inflammation and metabolic dysfunction contribute to elevated sympathetic activity, 
creating a vicious cycle, which exacerbates both metabolic and cardiovascular 
dysfunction Within the central nervous system, inflammation and hyperinsulinemia are 
associated with increased sympathetic nervous system (SNS) outflow (Smith & Minson, 
2012), which is elevated in obesity and PCOS (Lambert et al., 2010; Lansdown & Rees, 
2012; Dag et al., 2015). IL-6 receptors are present on sympathetic ganglia (Marz et al., 
1996; Gadient & Otten, 1996) and IL-6 infusions have been shown in to increase SNS 
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activity in humans (Torpy et al., 2000). Further, elevated TNFα increases the expression 
of IL-6 receptors on sympathetic neurons (Marz et al., 1996), and both cytokines are 
elevated in obesity (Roytblat et al., 2000; Tzanavari et al., 2010) and may be elevated in 
PCOS (Escobar-Morreale et al., 2011; Gao et al., 2016). Insulin also acts centrally to 
increase sympathetic outflow (Rowe et al., 1981; Anderson et al., 1992),  increasing the 
risk of hypertension in insulin-resistant populations such as women with PCOS (Luque-
Ramírez & Escobar-Morreale, 2014). High sympathetic outflow increases blood pressure 
through cardiac, renal, and arterial innervation, and SNS over-activity is considered an 
important risk factor for development of cardiovascular disease (Malpas, 2010). In 
addition, obesity-induced SNS over-activity contributes to end-organ damage in the 
kidney, blood vessels, and heart, increasing cardiovascular morbidity and mortality, even 
in the absence of hypertension (Lambert et al., 2010). Autonomic dysfunction is also 
implicated in ovarian dysfunction and androgen excess in PCOS (Lara et al., 1993; 
Sverrisdottir et al., 2008; Dag et al., 2015). Specific adipokines may also influence 
sympathetic overactivity (Smith & Minson, 2012), creating a vicious cycle of dysfunction 
that likely contributes to the cardiovascular and metabolic disturbances observed in obese 
women with PCOS (Shorakae et al., 2015; Spritzer et al., 2015). 
 12 
 
 
 
 
 
 
Figure 2. An overview of inflammation and ischemia in adipose tissue of obese 
women with PCOS. Excess fat storage, facilitated by high serum testosterone, leads to 
adipose tissue expansion, and the blood supply does not adequately match this tissue 
expansion. This adipocyte hypertrophy and inadequate blood supply causes adipocyte 
hypoxia, inflammatory cytokine release (IL-6, TNFα) by adipocytes and M1 
macrophages, a reduction in adiponectin release, and impaired insulin action. Low 
adiponectin promotes the pro-inflammatory profile of macrophages, and adipocytes 
and macrophages act in a paracrine fashion to further increase cytokine release from 
neighboring adipose tissue. Insulin resistance in adipocytes causes impaired 
suppression of lipolysis, and elevated serum catecholamines from sympathetic 
overactivity in PCOS further promote lipolysis. These fatty acids are released and 
deposited in other tissues such as skeletal muscle and liver. Partially oxidized fatty 
acids increase inflammation through proteins such as JNK and IKKβ in the liver and 
skeletal muscle, impairing insulin signaling in these tissues. Impaired insulin action in 
the liver leads to an increase in glucose release (impaired suppression of glycolysis), 
and in skeletal muscle leads to decreased glucose uptake (impaired GLUT-4 
translocation). The end result is hyperglycemia, hyperlipidemia, meta-inflammation, 
and insulin resistance. Filled arrows represent increased release or uptake, while 
unfilled arrows represent decreased release or uptake. Figure modified from Ely et al., 
2017. 
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Inflammation and systemic insulin resistance are also associated with impaired 
endothelium-dependent dilation and microvascular function (Steinberg et al., 1996; 
Scherrer & Sartori, 2000), observed in impairment of insulin’s actions on blood vessels 
(Laakso et al., 1990) as well as reduction in bioavailable nitric oxide (NO) due to the 
high oxidative stress seen in hyperinsulinemic individuals (Williams et al., 2002). The 
meta-inflammatory state of obese women with PCOS additionally causes impaired 
vascular remodeling, resulting in increased arterial stiffness (Safar et al., 2006) and 
intima media thickness (Dalmas et al., 2013). Intima media thickening is also associated 
with the dyslipidemia seen in obesity and PCOS throughout the lifespan (Diamanti-
Kandarakis et al., 2007; Magnussen et al., 2009).  
While various medications are prescribed for women with PCOS to alleviate 
symptoms related to menstrual dysfunction, androgen excess, and hyperinsulinemia, few 
interventions have specifically targeted inflammation or sympathetic nervous system 
activity to improve cardiometabolic risk profile. Recent work has examined the 
imidazoline receptor agonist Moxonidine in PCOS, which acts at the rostral ventrolateral 
medulla to reduce sympathetic outflow. This research was based on beneficial effects on 
hypertension, hyperinsulinemia, dyslipidemia, and inflammation observed in other 
populations (Prichard & Graham, 1997; Karlafti et al., 2013; Lambert et al., 2017). 
However, no improvements in blood pressure, sympathetic nervous system activity, 
insulin resistance, or C-reactive protein were seen when compared to placebo in obese 
women with PCOS (Shorakae et al., 2017). While anti-inflammatory drugs such as 
salicylates have been examined in other insulin resistant populations such as diabetics 
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(Williamson, 1901; Yin et al., 1998; Yuan et al., 2001), they have not been examined in 
PCOS related to reducing insulin resistance, vascular dysfunction, or circulating 
inflammatory markers. 
With limited pharmacological interventions to reduce sympathetic outflow and 
inflammation with PCOS, lifestyle interventions appear most promising. Exercise 
training and low-frequency electroacupuncture both substantially reduced muscle 
sympathetic nerve activity with a 16-week intervention in obese women with PCOS, 
while the exercise training group also experienced a decrease in BMI (Stener-Victorin et 
al., 2009). However; no change in blood pressure, fasting glucose, insulin, blood lipids, 
or hormones were observed with either intervention. Other exercise interventions in 
obese PCOS women have reported improvements in blood pressure (Vigorito et al., 
2007; Thomson et al., 2008), microvascular function (Sprung et al., 2013),  metabolic 
health parameters (Bruner et al., 2006; Vigorito et al., 2007; Giallauria et al., 2008; 
Palomba et al., 2008; Thomson et al., 2008), and inflammatory markers (Vigorito et al., 
2007; Giallauria et al., 2008; Covington et al., 2016) following 12-24 weeks of exercise 
training. The differences in health parameter improvements between studies may be due 
to the variety of intensity, duration, and mode of exercise training (Harrison et al., 
2011a), or the amount of weight loss accompanying the exercise training. In addition, 
recent work examining the efficacy of exercise training in overweight/obese women with 
or without PCOS found that the majority of women with PCOS (7 of 9) were classified as 
“non-responders” based on body mass change, and did not experience significant 
improvement in other metabolic health parameters including insulin sensitivity indices 
(Scott et al., 2017). This work highlights the need for alternative or adjunctive treatments 
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to improve cardiometabolic health in women with PCOS, as exercise training may not be 
sufficient to reverse the autonomic dysregulation and inflammatory patterns that 
contribute to substantial cardiometabolic dysfunction and risk in this population.  
 
How can chronic heat therapy help? 
Regular heat exposure, through sauna use, hot water immersion, or combined 
exercise heat stress, is associated with a variety of cellular and systemic adaptations that 
have potential to reduce inflammation and sympathetic outflow and thus improve 
cardiometabolic health in obese women with PCOS. In animal work, passive heat 
exposure with marked elevation in core temperature is associated with changes in protein 
expression and abundance that lead to enhanced cardiovascular and metabolic health, as 
well as cellular protection from a multitude of stressors (Horowitz & Assadi, 2010; 
Horowitz, 2014). Long-term passive heat acclimation (30 days) has been shown in animal 
models to initiate cellular pathways such as Heat Shock Proteins (HSP) and Hypoxia-
inducible Factor 1α (HIF1α) (Horowitz & Assadi, 2010; Horowitz, 2014) that enhance 
blood supply, protect cells from stressors such as ischemia (Maloyan et al., 2005), and 
reduce inflammation (Stice & Knowlton, 2008). In addition, altered expression of 
adipokines such as leptin and adiponectin have been observed in animals following 
repeated heat exposure (Morera et al., 2012). As such, there are multiple possible 
mechanisms by which heat therapy in humans could attenuate or prevent the development 
of insulin resistance, diabetes, and cardiovascular disease in obese women with PCOS. 
These mechanisms may work synergistically to intersect with the obesity-inflammation 
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cascade to potentially reduce ischemia, inflammation, insulin resistance, and vascular 
dysfunction.  
Ischemia, Inflammation, and Insulin Resistance. Seminal work in animals using 
long-term heat acclimation first described heat acclimation cross-tolerance, where long-
term passive heat acclimation protected cells from a multitude of stressors, including 
ischemia. This was first described in the rat heart, with a reduced infarct size in response 
to ischemia-reperfusion injury in heat-acclimated animals (Maloyan et al., 2005). Since 
then, interest in heat/hypoxia cross-tolerance has expanded (Ely et al., 2014) to include 
acute human studies of ischemia-reperfusion (Brunt et al., 2016d) and human 
performance models (Heled et al., 2012; White et al., 2016). It is thought that both HSPs 
and HIF1α play a role in protection from ischemic injury (Horowitz & Assadi, 2010).  
In obese women with PCOS, ischemia of hypertrophic adipocytes is among the 
first steps leading to cardiometabolic dysfunction. Chronic heat provides multiple 
avenues to improve blood supply (see Figure 3). For example, one downstream target of 
HIF-1α is vascular endothelial growth factor (VEGF) (Maloyan et al., 2005), which 
stimulates microvascular angiogenesis. Recent human work examining acute heat 
exposure demonstrated increased expression of various angiogenic signals including 
VEGF and angiopoietin after one 90-minute leg heating session, with concomitant 
increases in Hsp90 expression (Kuhlenhoelter et al., 2016). Hsp90 can also act through 
stabilizing endothelial nitric oxide synthase (Averna et al., 2008), and NO acts as another 
angiogenic signal (Papapetropoulos et al., 1997). In addition, NO production in 
endothelial cells is enhanced through shear stress (Thomas et al., 2017), as observed 
during acute heating. If blood supply to adipocytes is improved through some 
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combination of these mechanisms, adipocytes are less likely to become ischemic, which 
may attenuate the inflammatory response that comes from ischemia-induced hypoxia. 
While acute heat exposure may result in transient increases in pro-inflammatory 
compounds such as IL-6 (Faulkner et al., 2017) and JNK (Moon et al., 2003), chronic 
heat treatment has been shown to decrease intracellular levels of inflammatory proteins 
such as JNK and IKKβ (Gupte et al., 2009). Heat shock proteins have been linked with 
altered expression of pro- and anti-inflammatory cytokines (Cardillo & Ippolito, 2007; 
Dokladny et al., 2010), and decreases in other inflammatory compounds such as JNK and 
IKKβ in skeletal muscle (Gupte et al., 2009) in response to repeated heat exposure. IL-6 
and TNFα, both targets of HSPs, are elevated in PCOS and associated with impaired 
insulin signaling in adipose tissue (Greenberg et al., 1992; Hotamisligil et al., 1994; Kern 
et al., 2001). While JNK and IKKβ have not specifically been studied in adipose tissue of 
women with PCOS, they have both been shown in obesity to impair insulin signaling in 
skeletal muscle, liver, and adipose tissue in human and animal models (Hirosumi et al., 
2002; Arkan et al., 2005; Masharani et al., 2011).  
HSP levels have been linked to insulin sensitivity in humans (Bruce et al., 2003) 
through a variety of mechanisms. Individuals with type II diabetes exhibit reduced levels 
of HSPs in adipose tissue (Hooper & Hooper, 2009) and skeletal muscle (Bruce et al., 
2003). Animal work using regular heat exposure examined the relationship between 
various HSPs and insulin signaling in rat skeletal muscle, and found both Hsp27 and 
Hsp70 decreased inflammatory proteins such as JNK and IKKβ, both known to impair 
insulin signaling through serine phosphorylation of IRS-1 (Gupte et al., 2009). In adipose 
tissue, Hsp70 decreases the expression of nuclear factor kappa-B, which in turn reduces 
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the release of pro-inflammatory cytokines such as IL-1β, IL-6, and TNFα (Dokladny et 
al., 2010). Hsp70 is additionally involved in the protein refolding of the insulin receptor 
when denatured by stress (Zachayus et al., 1996), providing another mechanism through 
which heat shock proteins can improve or maintain insulin signaling in populations with 
impaired metabolic health. In skeletal muscle, mild heating increases expression of genes 
encoding mitochondrial biogenesis (Liu & Brooks, 2012), which can increase energy flux 
in the cell and reduce the accumulation of the fatty acid intermediates linked to 
inflammation and insulin resistance. In addition, animal work has suggested that as little 
as five days of passive heat exposure in mice increased serum adiponectin levels (Morera 
et al., 2012), which is associated with enhanced insulin sensitivity and reduce 
inflammation (Ouchi et al., 2003). 
In humans, hot water immersion has been examined as a therapeutic method in 
obese, diabetic individuals. Hooper (Hooper, 1992) examined glucose control in obese 
men and women with type 2 diabetes following three weeks of regular hot tub use (30 
minutes per session). The subjects experienced a large decrease in fasting glucose and 
glycosylated hemoglobin, and the researchers postulated that this was due to the 
increased blood flow to skeletal muscles during heating. While no mechanisms were 
examined in this study, similar heating protocols have been associated with increased 
HSP abundance in animal models (Gupte et al., 2009). Local heating of abdominal 
adipose tissue, when combined with mild electrical stimulation, has also been shown to 
reduce visceral fat storage and improve glucose tolerance in obese, diabetic individuals 
over a 12-week period (Kondo et al., 2014). These changes were additionally associated 
with reductions in inflammatory markers and an increase in Hsp72 abundance in 
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monocytes, linking the potential benefits of heat exposure on metabolic health to increase 
HSP production and reduced systemic inflammation. Further supporting the potential for 
regular heat exposure to reduce systemic inflammation, a large prospective cohort study 
in Finland (2,084 men) detailing sauna use habits found an inverse relationship between 
serum C-reactive protein and frequency of sauna use, even after correcting for factors 
such as BMI, diabetes, age, and physical activity (Laukkanen & Laukkanen, 2018). 
 
 
Figure 3. The potential pathways through which chronic heat exposure can reduce 
inflammation, improve blood flow, and reduce insulin resistance. The increases in 
shear, HSP90, and HIF1α all offer potential to improve blood flow and reduce adipose 
tissue hypoxia, through mechanisms such as increased nitric oxide (NO) and vascular 
endothelial growth factor (VEGF). In addition, HSP70 reduces inflammatory markers 
in both adipose tissue (nuclear factor kappa-B [NFκB], IL-6, and TNFα) and skeletal 
muscle (JNK), along with HSP27 (IKKβ). In addition, HSP70 is involved in protein 
refolding of the insulin receptor. In concert, these mechanisms can reduce 
inflammation, improve insulin signaling, increase glucose uptake and reduce fatty acid 
release, and increase adiponectin secretion, improving the metabolic health profile in 
obesity. While the changes in protein abundance and expression have been 
experimentally observed in human or animal models (denoted with boxes), some 
downstream effects have not specifically been examined in response to chronic heat. 
Figure from Ely et al., 2017. 
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Acute hot water immersion has since been studied as a means to improve glucose 
control. Faulkner and colleagues (Faulkner et al., 2017) compared the glucose response 
to a meal after either a 60-min hot bath or 60-min moderate intensity exercise in lean and 
overweight men, and found that heat decreased peak post-prandial glucose compared to 
exercise, with no difference in 24-h glucose control between heat and exercise. The 
authors postulated that increased HSP production in response to heat drove the improved 
glucose control through enhanced insulin signaling. 
While not a truly passive model of heat exposure, a series of studies have 
examined cardiometabolic risk factors after a hot yoga intervention, and reported 
improvements in body composition and glucose tolerance (Hunter et al., 2013a), 
cholesterol, insulin, and measures of vascular health (Hunter et al., 2013b; Guo et al., 
2014), and other markers of physiological and psychological well-being (Guo et al., 
2014). However, research is mixed on the increase in core temperature observed during a 
90-min Bikram yoga class (a series of 26 postures in a room set to 40.5°C, 40% relative 
humidity), with values ranging from mild hyperthermia [0.6-1.0°C increase (Pate & 
Buono, 2014)] to changes more similar to those seen in hot water immersion [1.7-2.5°C 
increase (Quandt et al., 2015)]. In addition, these hot yoga studies lacked a thermoneutral 
control group, and more recent research that employed a thermoneutral control group 
suggests these improvements in cardiovascular health are mediated by yoga rather than 
heat (Hunter et al., 2018). 
Vascular Dysfunction. In advance of overt cardiovascular disease, the high rates 
of obesity and insulin resistance in PCOS can increase cardiovascular dysfunction and 
blood pressure through impaired vascular remodeling (Ouchi et al., 2003; Osmond et al., 
 21 
 
2009), endothelial dysfunction (Steinberg et al., 1996), and elevated sympathetic nervous 
system activity (Smith & Minson, 2012; Canale et al., 2013). While the relative 
contributions of PCOS, obesity, inflammation, and metabolic dysfunction are difficult to 
tease apart, these elements combine to create an elevated risk of cardiovascular disease 
and cardiovascular death (Huxley, 2006; Wild et al., 2010). 
Heat therapy offers potential to attenuate or reverse impairment through a variety 
of mechanisms (see Figure 4). First, acute heating, through hot water immersion or sauna, 
promotes increases in cardiac output and redistribution of blood flow to the periphery as a 
cooling mechanism. This increase in skin blood flow alters the shear pattern of arterial 
blood flow through conduit vessels to increase anterograde shear and reduce retrograde 
shear (Carter et al., 2014; Thomas et al., 2016, 2017). This altered shear pattern has been 
shown to enhance vascular remodeling and endothelial function following exercise 
training (Laughlin et al., 2008; Tinken et al., 2009) and passive heating (Tinken et al., 
2009; Carter et al., 2014). Acute leg heating has also been shown in patients with 
symptomatic peripheral artery disease to enhance lower limb blood flow, reduce blood 
pressure and decrease circulating endothelin-1 (Neff et al., 2016), all of which can 
improve vascular health and function, particularly if heat is repeatedly applied over time. 
 Heat shock proteins also play an important role in cardiovascular protection. In 
vascular remodeling, Hsp27 reduces intimal hyperplasia (Connolly et al., 2003), an early 
step in formation of atherosclerotic plaques. Hsp72, through inhibition of Angiotensin II, 
reduces vascular smooth muscle hypertrophy (Zheng et al., 2006). Heat exposure has 
additionally been associated with reductions in IL-6 (Kim et al., 2005) and increases in 
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adiponectin (Morera et al., 2012), which promote and inhibit vascular inflammation, 
respectively. 
 
 
 
Figure 4. The potential pathways through which chronic heat exposure can improve 
cardiovascular health in the heart, macrovasculature, and microvasculature and 
autonomic activity in the brain. Increases in HSP90 and shear stress with heat therapy 
act to increase nitric oxide (NO), which can decrease sympathetic outflow, increase 
vasodilation in the microvasculature, and, along with HIF1α/VEGF, increase 
angiogenesis in the microvasculature. Increases in angiotensin II type 2 receptors 
(AT2) and adiponectin in the central nervous system can additionally reduce 
sympathetic outflow, which can decrease heart rate and peripheral resistance, reducing 
stress on the cardiovascular system. HSP27 and HSP70 decrease intimal and vascular 
smooth muscle (VSM) hyperplasia, and HSPs and HIF1α improve ischemic tolerance 
in the heart, reducing the risk or severity of cardiovascular events. Together, these 
mechanisms can reduce sympathetic outflow, reduce blood pressure, increase ischemic 
tolerance, and enhance vascular remodeling to improve the cardiovascular risk profile 
in obesity. Changes in shear stress, protein abundance and expression have been 
experimentally observed in human or animal models (indicated with boxes); however; 
some downstream effects have not specifically been examined in response to chronic 
heat. Figure from Ely et al., 2017. 
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 Endothelial function, in healthy populations, is predominantly dependent on the 
production of bioavailable NO (Tousoulis et al., 2012). Hsp90 is an essential cofactor for 
nitric oxide synthase stability (Averna et al., 2008), so increases in Hsp90 expression 
would likely lead to an increase in endothelial NO production, as seen in animal models 
(Harris et al., 2008; Bharati et al., 2017). In human models of vascular function, this 
increased NO production would enhance vasodilation as assessed by techniques such as 
flow-mediated dilation (Brunt et al., 2016c) and cutaneous local heating (Brunt et al., 
2016b). Since endothelial and cutaneous microcirculatory function (Steinberg et al., 
1996; Kraemer-Aguiar et al., 2008) are impaired in obesity and PCOS (Sprung et al., 
2013), even in advance of overt cardiovascular disease or hyperglycemia (Kraemer-
Aguiar et al., 2008), improving microcirculatory function is a promising means to 
improve cardiovascular health in obese women with PCOS. 
In humans, sauna has also been investigated as a means to improve vascular 
health both as an intervention in clinical populations and in prospective cohort studies. 
Classic Finnish saunas involve air temperatures of 80-100°C with low humidity, and 
individuals spend 5-30 minutes at a time in the sauna with brief breaks in a thermoneutral 
room between multiple bouts. A 30-min bout in an 80°C sauna quickly increases skin 
temperature and heart rate, and raises rectal temperature ~0.9°C (Leppaluoto, 1988). A 
single sauna exposure also reduces arterial stiffness and reduces blood pressure in men 
with at least one cardiovascular risk factor (Laukkanen et al., 2017; Lee et al., 2018). 
Two weeks of thermal therapy (60°C far-infrared sauna 6 days per week) in men with 
elevated cardiovascular risk significantly improved endothelial function, assessed via 
flow-mediated dilation (Imamura et al., 2001). A study in men with congestive heart 
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failure underwent the same therapy and similar improvements in flow-mediated dilation 
were observed (Kihara et al., 2002). In addition, brain natriuretic peptide (a marker of 
cardiac dysfunction) was significantly reduced following thermal therapy.  
Vascular health and function have also been examined in response to repeated 
passive heat exposure in healthy, inactive men and women. Brunt and colleagues (Brunt 
et al., 2016c) examined the effect of 8 weeks of hot water immersion (4-5 times per week 
for ~90 min per session, with core temperature increase of ~1.5˚C) and observed 
improvements in endothelial function, arterial stiffness, wall thickness, and blood 
pressure. In a companion study, this group also investigated cutaneous vasodilation in 
response to local heating as a model of microvascular function and specifically examined 
the role of NO (Brunt et al., 2016b), and observed an increase in cutaneous vascular 
conductance to thermal hyperemia that was primarily mediated by NO. The evidence is 
currently strong for heat therapy to improve vascular function and cardiovascular risk in 
both healthy and clinical populations. 
A large prospective cohort study (2,315 Finnish men) examined frequency and 
duration of sauna use and the correlation with mortality rates during a 20-year follow-up 
(Laukkanen et al., 2015). Increased frequency and duration of sauna use were associated 
with substantially reduced hazard ratios for sudden cardiac death, fatal coronary heart 
disease, fatal cardiovascular disease, and all-cause mortality. A follow-up study by the 
same group showed similar results for incident hypertension (Zaccardi et al., 2017). 
While these studies only examined men, did not include subjects that did not regularly 
use sauna, and did not specifically examine death related to metabolic diseases such as 
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diabetes, they are the largest and longest study to date on the potential long-term 
cardiovascular health benefits of regular passive heat exposure. 
The risk of cardiovascular death has not been examined in humans in an 
interventional study, but the underlying injury from myocardial infarction has been 
examined in human and animal models. Tissue death during cardiovascular or 
cerebrovascular events occurs due to ischemia-reperfusion (IR) injury, a complex cellular 
stressor of prolonged hypoxia followed by rapid reperfusion of tissue. Promising animal 
work in heat-acclimated rats has examined myocardial tissue death in response to IR 
injury and found vastly improved tissue survival following a 30-day passive heat protocol 
(Maloyan et al., 2005). Moreover, this improvement in tissue survival appeared to be 
directly related to the cytoprotective functions  of HSPs and HIF1α (Horowitz & Assadi, 
2010). In humans, an experimental model of IR injury in the arm using flow-mediated 
dilation as a model of vascular function has been used both in response to exercise 
(Seeger et al., 2015) and passive heat exposure (Brunt et al., 2016d), with both providing 
potent protection from IR stress. This is particularly important in obese women with 
PCOS, as obesity, metabolic dysfunction (Huxley, 2006),  and PCOS (de Groot et al., 
2011) disproportionately increase the risk of cardiovascular or cerebrovascular death in 
women. 
Autonomic Dysfunction. Sympathetic nervous system activity is implicated as a 
primary source of cardiovascular dysfunction in PCOS and strongly correlated with 
cardiovascular risk, and has the potential to be impacted by heat therapy. In addition, 
sympathetic outflow is inter-related with metabolic function in PCOS and obesity (Smith 
& Minson, 2012), suggesting that a reduction in sympathetic activity could have far-
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reaching benefits in women with PCOS. Autonomic outflow is regulated through a 
variety of neurological, neurohumoral, and psychological inputs, and can be modulated 
by a variety of hormones and compounds including adiponectin (Tanida et al., 2007), 
Angiotensin II (Wong et al., 1992), and NO (Patel et al., 2001). High circulating 
epinephrine suppresses insulin release from the pancreas and increases lipolysis and fatty 
acid release into the bloodstream (Porte, 1967). In turn, inflammation and 
hyperinsulinemia increase sympathetic outflow (Rowe et al., 1981; Anderson et al., 
1992), creating a positive feedback loop for both cardiovascular and metabolic decline in 
obese women with PCOS. Chronic heat exposure offers the potential to reduce 
sympathetic outflow through reductions in inflammation and insulin resistance as 
previously described, and can additionally reduce sympathetic activity through increasing 
circulating adiponectin (Morera et al., 2012) and enhancing central NO production 
(Pritchard et al., 2001; Harris et al., 2008; Bharati et al., 2017). Heat acclimation has 
additionally been shown, in murine models, to increase Angiotensin II receptor subtype 2 
(AT2) in the hypothalamus (Horowitz et al., 1999), which acts to reduce sympathetic 
outflow (Abdulla & Johns, 2017). These alterations in circulating adipokines, vasoactive 
substances, and receptor density have not been examined in human or animal models of 
PCOS in response to heat therapy, and very little human work has been done to examine 
autonomic function following heat acclimation. To date, the only human data examining 
the potential impact of heat adaptation on resting muscle sympathetic nerve activity 
(MSNA) is inferred from seasonal variation studies, with an observed decrease in MSNA 
in summer compared with winter attributed by the authors to warmer environmental 
temperature (Niimi et al., 1999; Cui et al., 2015). In rodent models, passive heat 
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acclimation was associated with increased parasympathetic and decreased sympathetic 
influence on autorhythmic cells, as measured by infusion of atropine and propranolol 
(Horowitz & Meiri, 1993), although sympathetic nerve activity was not directly assessed. 
Ovarian Function. In addition to potential improvements in cardiometabolic 
health in obese women with PCOS through reductions in inflammation and sympathetic 
activity, heat therapy may play a role in regulating ovarian function and potentially 
reducing PCOS symptoms. The possibility of reducing sympathetic outflow may not only 
reduce the risk of hypertension and cardiovascular disease, but high sympathetic activity 
is additionally implicated in cyst formation and androgen production (Lara et al., 1993, 
2005), so a reduction in sympathetic outflow may reduce PCOS symptomology. At the 
cellular level, recent work has highlighted altered expression of various HSPs in PCOS, 
including depressed circulating Hsp32 (also known as Heme-Oxygenase 1) (Gao et al., 
2014) and elevated circulating Hsp70 (Gao et al., 2013), as well as depressed ovarian 
Hsp10 (Ling et al., 2011) and elevated Hsp90B1(Li et al., 2016). Hsp90B1 appears to 
play a pivotal role in ovarian cell development (Li et al., 2016), with high levels in PCOS 
reducing autophagy and apoptosis, therefore promoting survival of abnormal oocytes. In 
contrast, women with PCOS tend to have lower Hsp10, which is involved in regulation of 
apoptosis in ovarian granuloma cells and contributes to ovarian dysfunction in PCOS 
(Ling et al., 2011). While changes in ovarian tissue has not yet been examined in human 
or animal models of PCOS with heat therapy, altered expression and abundance of  intra-
and extra-cellular HSPs have been observed in heat acclimation of both animals 
(Horowitz & Assadi, 2010; Horowitz, 2014) and humans (Yamada et al., 2007; McClung 
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et al., 2008; Magalhães et al., 2010; Amorim et al., 2015), providing a possible avenue 
for heat therapy to improve ovarian function in PCOS. 
In combination, heat therapy offers the potential to improve cardiovascular, 
autonomic, and metabolic health and reduce cardiometabolic risk through a variety of 
mechanisms, and may additionally offer relief from symptoms of PCOS related to 
ovarian dysfunction and excess androgen production. To date, research in humans has 
been limited, and no human or animal intervention has yet explored heat therapy in 
PCOS models. 
 
Summary  
The multifaceted decline in cardiovascular and metabolic function and the 
exacerbated cardiometabolic risk in obese women with PCOS deserves further study and 
requires novel interventions aimed at improving health. Heat therapy offers potential as a 
novel or adjunctive intervention to improve cardiometabolic health, reduce risk of 
cardiovascular or cerebrovascular death, and to potentially reduce the medical burden of 
both PCOS and obesity. While not offering a direct path to weight reduction, the 
reductions in inflammation, improvements in glucose tolerance, and improvements in 
vascular function that have been observed in human and animal models with chronic heat 
exposure provide a variety of avenues through which cardiometabolic health can be 
improved in the absence of weight changes. Further, the potential for heat therapy to 
reduce sympathetic activity and improve ovarian function in PCOS is a promising, 
unexplored area of research.  
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CHAPTER III 
EXPLANATION OF THE METHODOLOGY 
 
Overview of Project 
The research protocol involved obese women with Polycystic Ovary Syndrome 
undergoing a 30-session heat therapy intervention using hot water immersion (3-4 times 
per week over 8-10 weeks). Figure 5 shows an overview of the research timeline. An age 
and BMI-matched time control group did not undergo heat therapy but completed all 
testing days.  
 
Time-matched control group (no heat) 
8-10 weeks Heat Therapy (30 x 60 min sessions in 40.5˚C water) 
 
 
 
 
 
 
 
 
Figure 5. Overview of research timeline and vascular function, muscle sympathetic 
nerve activity (MSNA), oral glucose tolerance test (OGTT), and adipose biopsy study 
days for heat therapy and control subjects.  
Pre (0w; 0 sessions) 
Vascular Function 
MSNA 
OGTT 
Adipose biopsy 
Post (8-10w; 30 sessions) 
Vascular Function 
MSNA 
OGTT 
Adipose biopsy 
Mid (4-5w; ~15 sessions) 
Vascular Function 
MSNA 
OGTT 
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Subjects 
Young (age 18-39) women of all races and ethnicities were eligible to be recruited 
for participation in this study. All subjects provided oral and written informed consent 
prior to participation in the study, and all experimental procedures were approved by the 
Institutional Review Board at the University of Oregon. Potential subjects underwent a 
health screening to determine eligibility and had to meet all inclusion criteria, including a 
BMI ≥30 and ≤45 kg/m2, diagnosis with PCOS, non-smokers, not diagnosed with overt 
cardiovascular disease, and not taking prescription medications that affect insulin 
signaling or blood vessel function such as Metformin and Spironolactone, both of which 
are commonly prescribed in PCOS. Women taking oral contraceptives and anti-
depression/anti-anxiety medication were included. In all, eighteen subjects volunteered to 
participate and completed testing, with nine subjects assigned to the experimental group 
and nine to the time control group. Demographic information is presented in Table 1. 
 All Subjects (n=18) HT (n=9) CON (n=9) 
Age 27 ± 1 26 ± 2 27 ± 2 
BMI 41.3 ± 1.1 41.8 ± 1.4 40.7 ± 1.9 
Waist:Hip Ratio 0.85 ± 0.01 0.85 ± 0.01 0.86 ± 0.02 
Medications N=2 OCs 
N=4 SSRI 
N=1 OC 
N=2 SSRI 
N=1 OC 
N=2 SSRI 
    
 
 
Table 1. Demographics for heat therapy (HT) and control (CON) subjects 
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PCOS Diagnosis 
All subjects had been diagnosed with PCOS by a physician, and details of 
diagnosis were discussed during the initial subject screening visit. PCOS diagnosis is 
often made with differing sets of criteria. The initial criteria were set forth by the 
National Institute of Health (NIH) in 1990, and included clinical hyperandrogenism, 
oligo- or anovulatory amenorrhea, and exclusion of all other disorders which could cause 
these symptoms (Zawadski & Dunaif, 1992). The presence of polycystic ovaries with 
ovarian ultrasound was included in the updated Rotterdam criteria in 2003 (Rotterdam 
ESHRE/ASRM-Sponsored PCOS consensus workshop group, 2004). The Rotterdam 
criteria were created by a committee sponsored in part by the European Society for 
Human Reproduction and Embryology and the American Society for Reproductive 
Medicine, and these standards for diagnosis require two of the three defined hallmarks of 
PCOS: 1) clinical and/or biochemical hyperandrogenism, 2)  oligo- or anovulation, and 3) 
polycystic ovarian morphology. Guidelines have since been revised by the Androgen 
Excess Society (AES) (Azziz et al., 2006), with androgen excess considered a mandatory 
component in diagnosis, which could be accompanied by either ovulatory dysfunction, 
polycystic ovaries, or both. While some debate remains on the optimal diagnostic 
standards, most physicians use more recent Rotterdam criteria for diagnosis (2 of 3 
symptoms must be present). All women enrolled in the study were diagnosed with PCOS 
using these updated standards, and all reported bloodwork with elevated testosterone 
accompanied by polycystic ovarian morphology and/or oligomenorrhea. 
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Heat Therapy Intervention 
Heat therapy occurred over an eight to ten week period, with a total of 30 x one 
hour sessions scheduled three to four per week in all subjects enrolled in the experimental 
group (control subjects were not exposed to heat). This exposure duration and timeline 
was selected based on previous work in our lab, where promising improvements in 
vascular health were seen over an 8-week, 36 session heat therapy intervention (Brunt et 
al., 2016c). The acute exposure duration and total number of sessions were reduced 
slightly from our previous heat therapy work in order to create an intervention more 
similar in time commitment to exercise training protocols performed in women with 
PCOS (Harrison et al., 2011a). Hot water immersion was selected as the method of 
passive heat stress since our goal was to significantly raise core temperature, and it is 
difficult to achieve large increases in core temperature without exercise in warm/hot 
environments.  Passive hot water immersion is capable of increasing core temperature at 
a rate similar to moderate-intensity exercise (Kenny et al., 1996), while also facilitating 
high skin temperature and sweating rate, all requisite components for adaptation to heat 
(Fox et al., 1963; Buono et al., 2009). 
Subjects reported to the laboratory to undergo passive heating, which entailed 60 
min of water immersion to the sternoclavicular line in a bath set to 40.5°C. Previous 
research in our laboratory suggests this temperature is optimal to raise core temperature ≥ 
38.5°C within 20-30 minutes. This threshold was selected based on human heat 
acclimation literature using isothermic models (Fox et al., 1963), and is additionally 
important as a threshold for induction of heat shock proteins (Taylor, 2014). Once core 
temperature exceeded 38.5°C, subjects sat upright in the tub (immersed to the waist) for 
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the remainder of the one hour session in order to maintain core temperature between 
38.5-39.0°C. If temperature dropped below 38.5, subjects were asked to submerge again. 
After 60 minutes of exposure, subjects were asked to sit next to the tub until core 
temperature fell below 38.5˚C (10-15 minutes) for safety monitoring, and for monitoring 
the total exposure duration where core temperature was above 38.5°C. A representative 
tracing of core temperature during a single heat therapy session is seen in Figure 6. 
Time
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C
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37.6
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38.4
38.6
38.8
immersed to neck 
Immersed to waist 
Out of tub 
Figure 6. Representative tracing of rectal temperature (Tre) over time during a single 
hot tub session and recovery. 
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Upon arrival, subjects provided a urine sample (ideally first-void) for 
measurement of specific gravity (USG) to confirm euhydration (USG ≤ 1.02) prior to 
heat exposure. Subjects were also weighed pre- and post-heat exposure (nude, towel-
dried, behind a privacy screen) and given water to drink ad libitum during heat exposure 
and post-heat exposure if necessary to match fluid losses. Heart rate was monitored 
throughout heating using commercially-available heart rate monitors (Polar), while core 
temperature was monitored throughout passive heating by rectal thermistor (rectal 
temperature, Tre). Rectal thermistors were used over less invasive methods such as aural 
or tympanic temperature due to safety-driven desire for a more accurate recording of 
deep body temperature. 
 
Cardiovascular, Autonomic, and Metabolic Health Assessment 
All study days took place in a thermoneutral lab environment, 24-72 hours after 
the most recent heat exposure in experimental subjects. While time of day varied between 
subjects due to work and class conflicts, time of day was held constant (within 1 hr) for 
each subject over time in order to minimize circadian influence. Subjects reported to the 
lab having refrained from food for a minimum of four hours (12 hours for OGTT 
studies), caffeine and alcohol for 12 hours, vitamin supplementation, all medications 
other than oral contraceptives, and exercise for 24 hours prior to the start of testing. Body 
mass and height were measured, and a urine sample was collected for confirmation that 
the subject was not pregnant prior to beginning testing. On one testing day at each time 
point, subjects were additionally assessed for waist circumference, hip circumference, 
and three site skinfold thickness for estimates of waist to hip ratio and body composition. 
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On vascular function and MSNA days, subject rested on a padded exam table for a 
minimum of 20 minutes prior to beginning testing, and during this time they were 
instrumented with a 3-lead ECG, brachial blood pressure cuff, and beat-by-beat blood 
pressure monitor (Nexfin) 
 
Vascular Function 
Vascular health was measured in all subjects using a variety of assessments and 
techniques. Measures of arterial wall thickness, dynamic arterial compliance, and flow-
mediated dilation were all measured using doppler ultrasound. Vascular ultrasound 
applies the principles of sound wave reflection and doppler shift to allow simultaneous 
measurement of arterial diameter and blood velocity. The ultrasound probe contains a 
piezoelectric element which converts electrical signals into mechanical vibrations, then 
measures sound wave reflection of these vibrations to convert sound waves into 
measurable electrical signals (Pellerito & Polak, 2012). The Terason t3000cv system uses 
a 10 MHz linear array probe to capture blood vessel diameter and velocity, and these 
images are video recorded for offline analysis using custom wall-tracking and velocity 
tracking software (DICOM, Perth, Australia). Briefly, a region of interest on the artery is 
selected for wall tracking (see yellow lines in arterial image in Figure 7, which track the 
bright vessel walls), and blood velocity was measured in a nearby location by selecting a 
velocity gate. DICOM traces peak blood velocity (lower panel of Figure 7), which is then 
used along with diameter to calculate total flow [Flow in mL/min = ½ Velocity in 
cm/sec*π*(radius in cm)2*60sec/min] and shear rate [Shear rate=4*Velocity/Diameter]. 
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Wall thickness. Wall thickness of the common carotid artery is a well-described 
measure of vascular health (Simova, 2015),  a strong predictor of future cardiovascular 
events (Lorenz et al., 2007), and is responsive to a passive heat therapy intervention in 
healthy, inactive individuals (Brunt et al., 2016c). Further, both carotid and femoral wall 
thickness are increased in obesity (Dalmas et al., 2013) and PCOS (Lakhani et al., 2004; 
Meyer et al., 2012; Allameh et al., 2013). Wall thickness was developed as a surrogate 
marker for predicting atherosclerosis, and has the advantage of being less invasive than 
angiography, and better able to detect small changes in the early stages of wall thickening 
before atherosclerotic plaque development (de Groot et al., 2004). The common carotid 
and superficial femoral artery were imaged using high-resolution Doppler ultrasound 
(Terason t3000cv; Teratech, Burlington, MA, USA) in B mode with 10.0 MHz linear 
array ultrasound transducer probe artery. The carotid artery was imaged 2 cm distal to the 
carotid bulb at three angles: anterior, lateral and posterior. The superficial femoral artery 
was imaged 2–4 cm distal to the femoral bifurcation in two planes: anterior and lateral. 
Clearly distinguished intimal–medial boundaries were obtained while focusing on the far 
Figure 7. Sample analysis of arterial diameter (upper image) and 
velocity (lower image) using DICOM. 
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wall. Images were frozen in diastole and enlarged, and calipers were used to make three 
repeat measurements of the wall thickness from the lumen–intima interface to the media 
adventitia interface (see Figure 8). Video recording of these measurements was later 
reviewed offline to confirm accuracy of caliper measurement, and three measurements 
from each angle were averaged. 
  
 
Arterial Stiffness. Arterial stiffness was assessed using several different methods, 
including carotid-femoral and brachial-ankle pulse wave velocity (PWV), as well as 
common carotid and superficial femoral dynamic arterial compliance (DAC). Pulse wave 
velocity is considered to be the simplest, most robust, and reproducible measure of 
arterial stiffness (O’Rourke et al., 2002; Laurent et al., 2006), is impaired in obese 
women with PCOS (Ketel et al., 2010; Sasaki et al., 2011), and has been shown to 
decrease with a chronic heat intervention in healthy, inactive individuals (Brunt et al., 
2016c). In addition, carotid-femoral PWV has been validated for predicting 
cardiovascular outcomes in a variety of disease conditions (Ben-Shlomo et al., 2014). In 
obese populations where central adiposity may interfere with acquisition of clean femoral 
Figure 8. Image of common carotid wall (left) and zoomed image of measurement. 
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pulse tracings, brachial-ankle PWV is a reasonable surrogate of central arterial stiffness, 
while providing additional information about peripheral artery stiffness (Sugawara et al., 
2005). DAC, while less commonly used in clinical settings, has also been reported as 
impaired in women with PCOS (Soares et al., 2009), and to respond to repeated heat 
exposure in healthy and clinical populations (Brunt et al., 2016c; Hunter et al., 2017). 
Pulse wave velocity was assessed using applanation tonometry with pressure transducers 
(PCU-2000; Millar, Inc., Houston, TX, USA) placed on the carotid & femoral arteries (C-
F; central PWV or aortic stiffness), as well as the brachial and dorsal pedal arteries (B-A; 
peripheral PWV).  Tracings were recorded using data acquisition software (Windaq; 
Dataq Instruments, Akron, OH, USA), and the pulse upswings of a minimum of thirty 
simultaneously recorded pressure tracings were identified offline by a blinded 
investigator in order to calculate the time differential (See figure 9). Velocity was 
calculated as distance over time, where distance was the sum of the linear distances 
between the carotid probe and the sternal notch and the sternal notch to the femoral probe 
(carotid-femoral) or the distance differential between the brachial probe to sternal notch 
distance and the ankle probe to sternal notch distance (brachial-ankle).  
Carotid and femoral DAC were measured using high-resolution Doppler 
ultrasound (Terason t3000cv; Teratech, Burlington, MA, USA) with 10.0 MHz linear 
array ultrasound transducer probe with concurrent applanation tonometry on the same 
artery on the contralateral side of the body. Ultrasound probe placement on the body, 
including angle of approach and internal anchors such as distance from bifurcation, were 
recorded on the first trial day and repeated to ensure consistency between repeated 
measurements over the course of the study. All ultrasound recordings were performed on 
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the right side of the body. Ultrasound images were recorded at 20 Hz using video 
recording software (Camtasia), then analyzed for diameter and blood velocity using 
custom-designed edge detection and wall tracking software (DICOM; Perth, Australia). 
Pulse pressure using applanation tonometry was simultaneously recoded via Windaq data 
acquisition (Dataq, Inc) at 250 Hz, and analyzed using the trough to peak pressure 
differential. This pressure differential (∆P) was then analyzed relative to change in 
diameter (∆D) for a minimum of 50 cardiac cycles in order to calculate cross-sectional 
compliance and β stiffness using the following equations:  
Dynamic arterial compliance = [(∆D/D)/2∆P] * πD2 
Β-stiffness index = Ln (SBP/DBP)*D/∆D 
 
Figure 9. Sample pulse tracings with time differential (left) and distance 
measurement (right) used for PWV. 
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Endothelial Function. Endothelial function was assessed using flow-mediated 
dilation (FMD), a technique developed in 1992 by Celermajer and colleagues as a non-
invasive means to assess endothelium-dependent vasodilation in children and adults 
(Celermajer et al., 1992).  FMD consists of arterial imaging by Doppler ultrasound to 
obtain baseline diameter and blood velocity measurement, then inflating an occlusion 
cuff just below the artery for a period of 5 minutes. Following release of the cuff, a large 
increase in blood flow occurs, creating shear stress on the blood vessel walls, and 
changes in velocity and diameter are captured using doppler ultrasound for three minutes 
after cuff release.  FMD is defined as the maximal change in diameter observed in 
response to the 5-min occlusion of blood flow distal to the brachial artery, with a larger 
% change in diameter indicating greater endothelial function and reduced cardiovascular 
risk. FMD is a well-established predictor of cardiovascular risk and future cardiovascular 
events (Yeboah et al., 2008; Shechter et al., 2009). While dilation occurs predominantly 
due to the release of nitric oxide induced by shear stress acting on the endothelial cells, 
FMD is not exclusively NO-dependent (Wray et al., 2013), and some debate exists on 
whether it is an optimal test of endothelial function or bioavailable NO. However, it is 
used in both research and clinical settings, and, importantly, FMD at the brachial artery 
has been shown to parallel coronary artery endothelial function (Teragawa et al., 2005). 
Additionally, in previous work in our lab, FMD improved with heat therapy in healthy 
humans (Brunt et al., 2016c). 
FMD was measured at the brachial artery using Doppler ultrasonography 
according to established methodology (Thijssen et al., 2011), with an occlusion cuff 
placed just distal to the elbow and inflated to 250mmHg for a period of five minutes. The 
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ultrasound images were recorded (Camtasia software) for one minute of baseline (prior to 
cuff inflation), and for three minutes after release of the cuff. The recorded images were 
analyzed for changes in brachial artery diameter and blood velocity using DICOM 
analysis software. Variables of interest included baseline diameter, peak diameter, and 
blood velocity at baseline and from cuff release to peak diameter. Velocity and diameter 
were used to calculate shear rate (blood velocity ÷ diameter) and shear area under the 
curve (defined as the sum of shear rate over time from cuff release to peak dilation, 
minus baseline shear rate) in order to assess the shear stimulus for vasodilation. FMD % 
dilation is commonly expressed in both absolute percentage, and shear-corrected (FMD% 
÷ shear area under the curve) in order to quantify the response relative to the 
dose/stimulus of shear stress (Padilla et al., 2008). 
 
Ischemia/Reperfusion. In addition to being a well-established test of endothelial 
function, FMD is responsive to stress such as ischemia-reperfusion (IR) (Seeger et al., 
2015; Brunt et al., 2016d). Since women with PCOS are at an elevated risk of coronary 
Figure 10. DICOM analysis software allows arterial diameter and velocity tracking during 
FMD (see yellow wall tracking of brachial artery in upper left panel). Upon release of the 
cuff, a large increase in velocity (lower left panel) creates a shear stimulus that leads to an 
increase in diameter. The right panel displays a sample analysis of baseline diameter, peak 
diameter (for calculation of FMD%), and shear AUC (highlighted in lower panel) for 
calculation of shear AUC between cuff release and peak diameter. 
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or cerebrovascular events, blood vessel responsiveness to IR is an important variable to 
assess future risk of cardiovascular/cerebrovascular death.  IR was performed by placing 
an occlusion cuff on the upper arm (above the point where the brachial artery was imaged 
for FMD) and inflating it to 250mmHg for a period of 20 minutes. Twenty minutes after 
release of the cuff, FMD was re-assessed. This protocol was selected as it has been used 
in acute exercise (Seeger et al., 2015) and heat (Brunt et al., 2016d) interventions, has 
been well-tolerated by subjects, and shows a short-term impairment of endothelial and 
microvascular function. 
Autonomic Function 
Muscle Sympathetic Nerve Activity. Muscle sympathetic nerve activity (MSNA) 
was first described in 1977 (Sundlöf & Wallin, 1977), and proposed as a global measure 
of sympathetic nerve activity that correlated well with plasma norepinepherine 
concentrations (Wallin et al., 1981) and acutely tracked with changes in diastolic blood 
pressure (Sundlöf & Wallin, 1978). Since its inception, MSNA has been used in 
laboratories throughout the world to assess postganglionic sympathetic nerve traffic in 
clinical populations and in response to interventions. MSNA bursting rates (expressed as 
burst frequency; bursts/min, and burst incidence; bursts/100 heartbeats) are correlated 
with both the risk (Rea & Hamdan, 1990) and severity (Matsukawa et al., 1993) of 
hypertension, and are associated with obesity-induced sub-clinical organ damage 
(Lambert et al., 2010). In women with PCOS, this measure is particularly important as 
sympathetic overactivity is implicated in the pathogenesis of the disease (Lansdown & 
Rees, 2012), and is likely related to the elevated risk of hypertension and other 
cardiometabolic disturbances in this population.                                                      
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MSNA was assessed in resting subjects in the peroneal nerve as previously 
described (Wallin & Sundlof, 1979). Subjects were instrumented with a 3-lead EKG, 
brachial blood pressure monitor, and beat-by-beat blood pressure monitor while resting 
supine on a padded exam table. The leg was slightly elevated from mid-thigh and held 
stable using a vacuum splint on the thigh and a raised footrest while the subject was 
supine, in order to easily access the regions behind the knee and near the fibular head 
where the nerve runs closest to the skin surface. The peroneal nerve was located using 
external stimulation, tracing the nerve from the fibular head through the popliteal fossa, 
and sites that showed strong muscle twitches were identified. Once a site was selected, a 
tungsten microelectrode (FHC, Bowdoin, ME) was inserted percutaneously into the 
peroneal nerve and manipulated until postganglionic sympathetic nerve traffic was 
recognized. Muscle sympathetic nerve activity was distinguished from other sources of 
nerve activity by the following criteria: 1) presence of spontaneous pulse synchronous 
bursts, peaking approximately 1.1-1.4 seconds after a QRS complex, 2) increased activity 
during breath hold or Valsalva straining, 3) confirmation of muscle afferent activity 
during light passive dorsiflexion of the foot, and 4) confirmation of a lack of skin nerve 
activity during light stroking of the skin on the foot and shin. Nerve recording was 
considered optimal with a 3:1 signal:noise ratio and a stable baseline. See Figure 11 for 
example of MSNA recording at rest, including stable baseline, ≥3:1 signal: noise ratio, 
and timing of bursts with the EKG and with blood pressure fluctuations.  
Nerve traffic was continuously recorded at 250 Hz and analyzed offline by two 
investigators (one blinded) for burst frequency and incidence. Measures were taken at 
baseline (quiet supine resting), with paced breathing (resting while breathing to a 
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metronome set to 15 breaths/min), and during a Valsalva maneuver as an assessment of 
baroreflex function. While our primary autonomic outcome variables were burst 
frequency and incidence at rest and during pace breathing, the possibility that heat 
therapy would cause a large change in baseline MSNA necessitated examination of 
sympathetic responsiveness. This allows insight into whether heat therapy altered the set 
point for blood pressure, or whether baroreflex sensitivity is altered as well. 
 
Valsalva Maneuver. The Valsalva maneuver, named for 17th century physician 
Antonio Maria Valsalva, involves forceful expiration (‘bearing down’) against a closed 
glottis. This maneuver causes dramatic changes in intrathoracic pressure, and 
physiological responses can be divided into four phases. Phase I begins at the onset of 
Valsalva straining, where a transient increase in stroke volume secondary to an increase 
Figure 11. Sample MSNA recording during rest (upper tracing; sharp deflections 
represent SNS firing to muscle vascular beds), with ECG (middle) and beat-by-beat 
blood pressure (lower).  
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in intrathoracic pressure causes a temporary rise in blood pressure. However, this phase is 
short-lived as venous return decreases, causing blood pressure to drop and MSNA burst 
frequency to increase in an attempt to maintain pressure through increased 
vasoconstriction and heart rate. Phase III begins at the release of straining, which results 
in decreased intrathoracic pressure and a brief decrease in blood pressure before Phase IV 
(blood pressure overshoot with decreased heart rate), and resolves when blood pressure 
and heart rate return to baseline (see Figure 12 for sample tracing). 
 
This maneuver is used during MSNA to assess baroreflex function by examining 
changes in MSNA relative to changes in diastolic pressure (sympathetic baroreflex 
sensitivity; sBRS), and changes in the ECG R-R interval relative to systolic pressure 
(cardiovagal baroreflex sensitivity; cBRS). The arterial baroreflex is important in the 
Figure 12. Sample MSNA recording during the Valsalva maneuver, with MSNA 
(upper panel), heart rate (middle panel), and blood pressure (lower panel) and four 
phases identified. 
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regulation of blood pressure during various challenges, including orthostasis and exercise 
(Eckberg & Sleight, 1992).  
When blood pressure drops (as in Phase II of the Valsalva maneuver), 
sympathetic outflow increases and leads to cardiovascular adjustments including 
vasoconstriction of arterioles and tachycardia in an attempt to restore blood pressure. A 
linear regression of the change in blood pressure relative to the change in MSNA or heart 
rate during Phase II of the Valsalva maneuver allows for assessment of baroreflex 
sensitivity by examining the slope of regression line. While this can additionally be 
examined in Phase IV (blood pressure is elevated while heart rate is depressed), it is 
common to have very few sympathetic bursts during the blood pressure overshoot, 
making calculation of a slope difficult for sympathetic baroreflex sensitivity.  
Subjects were instructed to rest for one minute while breathing normally, then 
perform a 20-second Valsalva maneuver by contracting their abdominals, bearing down 
with a closed glottis, and blowing into a tube connected to a pressure transducer 
(details?). The pressure gauge was connected to a CardioCap monitor, and subjects were 
instructed to keep pressure at 40mmHg for 20 seconds. At the end of 20 seconds, the 
subject resumed normal breathing, and MSNA and blood pressure were monitored for an 
additional 60-120 seconds, until heart rate and beat-by-beat blood pressure appeared to 
return to baseline. Change in MSNA, blood pressure, and heart rate during Valsalva 
straining and release provide insight into autonomic regulation. In general, a greater 
baroreflex sensitivity (steeper slope) is associated with a healthier cardiovascular risk 
profile (Eckberg & Sleight, 1992; Sleight, 1997). 
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Heart Rate Variability. Due to the difficulty in obtaining nerve tracings in some 
subjects, we additionally assessed autonomic function using heart rate variability at rest 
and during paced breathing in all subjects. Spectral analysis heart rate variability is a 
widely-used, non-invasive, estimate of autonomic influence on the heart. While its 
correlation with MSNA and cardiac NE spillover is poor (Kingwell et al., 1994) in 
clinical populations, measures of low-frequency variability (LFnu; attributed to high 
sympathetic activity) do track with MSNA in healthy individuals in select conditions 
(DeBeck et al., 2010). In addition, overall variability and high-frequency variability 
(HFnu; attributed to parasympathetic activity) appear to be decreased, indicating reduced 
parasympathetic influence, in women with PCOS (Hashim et al., 2015; Ribiero et al., 
2016). As such, we measured HRV in all subjects during MSNA studies, and in subjects 
in whom we were unable to obtain adequate nerve recordings. Briefly, subjects were 
resting in the supine position in a dark, thermoneutral room (18-21°C) for a minimum of 
20 minutes prior to testing. Heart rhythm was measured using a 3-lead EKG (CardioCap; 
Datex Ohmeda, Louisville, CO) while breathing to a metronome paced at 15 breaths/min 
for five minutes.  Data were continuously recorded at 250Hz (Windaq, Dataq 
Instruments, Akron, OH) for offline analysis including peak detection of R waves and 
examination of heart rate variability using commercially available software 
(HRVanalysis 1.1) (Pichot et al., 2016). Variables of interest within time domain 
analyses of total variability included the standard deviation of normal-to-normal R-R 
intervals (SDNN) and the square root of the mean sum of squared differences (rMSSD).  
Frequencial analyses were additionally employed to measure total variability (Ptot) and 
to estimate the relative contribution of parasympathetic and sympathetic 
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modulation using low frequency (LF, LFnu; defined as 0.04-0.15Hz), high frequency 
(HF, HFnu; defined as 0.15-0.4Hz), and the ratio of low to high frequency (LF/HF). 
 
Alternative Techniques. While MSNA is the most direct assessment of 
sympathetic nerve traffic available in humans, there are several alternative approaches to 
measure or estimate sympathetic activity. These include serum catecholamines, urinary 
excretion of catecholamine metabolites, whole-body (Straznicky et al., 2016) or organ-
specific norepinephrine spillover (Esler et al., 1984). Serum and urine catecholamine 
levels are a global estimate of sympathetic activity; however; there are a variety of 
situations in which these measures do not adequately reflect changes in sympathetic 
outflow (Young et al., 1984). Cardiac norepinephrine spillover allows for acute 
examination of cardiac sympathetic activity, which is well-correlated with MSNA. While 
this technique more specifically measures sympathetic activity to the heart as compared 
to muscle vascular beds, it is expensive and invasive, requiring radiotracers and cardiac 
catheterization. Global norepinephrine spillover, while less organ-specific, tracks with 
changes in sympathetic activity (Straznicky et al., 2010, 2016), but similarly requires 
radiotracers and arterial catheterization. 
For assessment of baroreflex sensitivity, the gold standard assessment is the 
Modified Oxford technique, which involves sequential intravenous infusion of 
nitroprusside and phenylephrine to create systemic vasodilation and vasoconstriction, 
respectively (Rudas et al., 1999). These changes in vascular tone cause dramatic 
fluctuations in blood pressure, which are sensed by baroreceptors that alter sympathetic 
and parasympathetic outflow in order to maintain pressure. The change in MSNA and 
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heart rate during these vasoactive drug infusions allow for assessment of sBRS and cBRS 
in a tightly controlled research environment through a wide range of pressures that allow 
for consistent, reliable baroreflex slopes (Hart et al., 2010). The one limitation of this 
technique is that nitroprusside is not exclusively a vasoactive substance (Hogan et al., 
1999; Kienbaum & Peters, 2004). In addition, the technique is relatively invasive and 
drug infusions can interfere with other tests performed after the Modified Oxford, 
therefore simpler approaches such as baroreflex threshold analysis (calculated during 
rest)  have been examined as non-pharmacological assessments of baroreflex sensitivity 
during MSNA (Hart et al., 2010). Spontaneous baroreflex sensitivity also correlates well 
with measures made during the Valsalva maneuver (Yang & Carter, 2013). Provided that 
a reasonable range of blood pressures are present during recording, all measures are valid 
assessments of the baroreflex. 
 
Metabolic Function 
Oral Glucose Tolerance Test (OGTT). An OGTT is a commonly used clinical tool 
to assess glucose tolerance and estimate insulin sensitivity. Selection of a 2-hr, 75 gram 
OGTT was based on its wide clinical utility, well-established thresholds for impaired 
fasting glucose and impaired glucose tolerance, and its inclusion as part of recommended 
screening for all obese women diagnosed with PCOS (Azziz et al., 2006).  The standard 
glucose dose (75 grams in a 10-oz beverage) and blood sampling points allow 
examination of blood glucose and insulin over time in order to build a curve for each over 
a two hour period. Optimal values include a fasting blood glucose <100mg/dL, and a 2-hr 
glucose under 140 mg/dL. Values that exceed this range indicate impaired fasting glucose 
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or impaired glucose uptake. In addition, as the slope of the early rise (0-30 min) in blood 
glucose and insulin are indicative of hepatic glucose sensitivity (suppression of 
endogenous glucose production), and the slope of decrease in glucose from 60 to 120 
minutes are indicative of peripheral tissue (primarily skeletal muscle) glucose uptake, the 
area under the curve (AUC) for glucose and insulin provide insight into whole-body 
insulin sensitivity (Abdul-Ghani et al., 2007). 
Subjects arrived at the laboratory following an overnight fast (≥12hr) and having 
refrained from caffeine and alcohol for 12 hours, vitamin supplements and medications 
for 24 hours, and heavy exercise or heat exposure for >24 hours. In addition, diet was 
recorded using a 24-hour food recall to ensure similar macronutrient composition 
between tests for each subject. After 15 minutes of seated rest, a venous catheter was 
inserted into a vein in the antecubital space or hand and baseline samples were drawn into 
syringes, then placed into appropriate tubes. After baseline (fasted) sampling, a 75-g 
glucose drink was ingested in a 2-5 minute period, and blood samples were taken at 15, 
30, 45, 60, 90, and 120 minutes for blood glucose, and insulin. The resulting glucose and 
insulin curves provide an indication of glucose tolerance and insulin sensitivity through 
measurement of the area under the curve for both glucose and insulin. In addition, 
commonly used fasting markers of insulin resistance were calculated as assessments of 
insulin resistance (Piché et al., 2007). These included the homeostatic model assessment 
for insulin resistance (HOMA-IR=[glucose mg/dL*insulin mU/L]/405) and quantitative 
insulin sensitivity check index (QUICKI=1/[Log(glucose) +Log(insulin)]), both 
calculated based on values obtained after a 12-hr overnight fast. 
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Samples were placed in EDTA tubes for analysis of glucose using the glucose 
oxidase method (YSI 2300 Stat Plus, Yellow Springs, OH) and serum separator tubes 
(SST) for analysis of insulin. The EDTA tubes were immediately placed on ice and 
centrifuged, while the SSTs were allowed to clot at room temperature for 30 minutes 
prior to centrifugation. All samples were centrifuged at 1500 x g for 10 minutes at 4°C, 
and plasma or serum was aliquoted into cryovials and placed in -80°C freezer. 
Alternative Techniques. While the 2-hr, 75g OGTT is a widely used clinical 
measure to assess glucose tolerance and screen for Type II diabetes, the “gold standard” 
assessment for insulin sensitivity in research is the Euglycemic-Hyperinsulinemic clamp 
technique. This technique was developed in 1979 by Defronzo and colleagues (DeFronzo 
et al., 1979). The procedure involves infusing a standard insulin dose, and then 
measuring the glucose infusion rate required to maintain euglycemia in order to calculate 
whole-body glucose disposal rate as a measure of insulin sensitivity. While this technique 
is more commonly used in research rather than clinical settings, thresholds for insulin 
resistance have been established (Tam et al., 2012). Correlation between results obtained 
with this technique and with indices obtained from an OGTT are good (Stumvoll et al., 
2000; Piché et al., 2007), with the strongest correlations in those with some degree of 
insulin resistance (Piché et al., 2007). The drawbacks of this assessment include the 
assumption of complete suppression of hepatic glucose production, a standard insulin 
infusion that may not be able to detect differences between extremely insulin-resistant 
populations, and the insulin infusion representing a non-physiological concentration for 
many populations (Muniyappa et al., 2008). Additional considerations include time, cost, 
and highly specialized supervision requirements.  
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Adipose Tissue Biopsies. Adipose tissue inflammation and dysfunction are 
common in obesity (Hodson et al., 2013), insulin resistance (Hotamisligil et al., 2017), 
and PCOS (de Zegher et al., 2009; Villa & Pratley, 2011; Echiburú et al., 2018), and 
improvements in systemic glucose tolerance or insulin resistance in response to an 
intervention are often apparent in adipose tissue biopsies in human (Bruun et al., 2006; 
Albers et al., 2015a) and animal studies (Rogers et al., 2015). Therefore, we examined 
subcutaneous adipose tissue biopsies before and after heat therapy or time control in 
order to examine tissue-specific mechansisms to support possible changes in whole-body 
measures of glucose tolerance, insulin sensitivity, and inflammation. The selection of 
subcutaneous fat sampling from the umbilical region was driven by ease of sampling and 
comfort of participants. The abdominal region was selected over the gluteal region due to 
greater central obesity in PCOS. While visceral fat appears to have a stronger relationship 
with metabolic dysfunction (Wajchenberg et al., 2002) and insulin resistance (Preis et al., 
2010) in obesity, obese women with PCOS exhibit dysfunction in both visceral and 
subcutaneous depots in the abdominal region (Echiburú et al., 2018). Further, due to the 
location of visceral fat depots, sampling is only performed in humans undergoing 
abdominal surgery (Camastra et al., 2017), such as gastric bypass or gall bladder 
removal. 
Subcutaneous white adipose tissue samples were obtained after a 4-hour fast from 
the peri-umbilical area. The sampling area was cleaned with antiseptic (Chloraprep) and a 
local anesthesia was induced by intracutaenous and subcutaneous injection of 5ml of 1% 
lidocaine near the site of incision in the side of the umbilicus. Following local anesthesia, 
a 3mm wide skin incision was made with a sterile scalpel at the edge of the umbilicus, 
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and 15 cm long, 16 gauge infiltration cannula (Millenium Surgical, Narbeth, PA) was 
advanced through the incision. This cannula was connected to a 60-ml syringe containing 
a mixture of 50 ml of 0.9% sterile saline and 7.5mL of 1% lidocaine. This fluid was 
injected in the subcutaneous fat in a fan-like fashion from the incision site, covering a 
total area of ~5x5cm. Next, an 11 gauge aspiration cannula (Millenium Surgical, Narbeth, 
PA) connected to a 20mL sterile syringe was advanced in the same fan-like fashion while 
gentle suction was applied. A total sample of 10-12mL of fluid and fat was taken, 
resulting in an adipose tissue sample of 4-7mL. This sample was collected and washed 
three times in sterile saline before a portion of whole adipose tissue was snap-frozen in 
liquid nitrogen for later analysis of HSPs and inflammatory markers. The remaining 
sample was placed in phosphate-buffered saline (PBS) for adipocyte isolation.  
 Adipocytes were isolated by digesting tissue with collagenase (1mg/mL in KRH 
buffer) at 37°C. When tissue chunks were no longer visible, the sample was passed 
through a 250um Pierce tissue strainer (Thermofisher Scientific, Rockford, IL) and 
washed with an equal volume of wash buffer (KRH buffer with 10uL adenosine and 2% 
BSA) before centrifugation at 500 x g for 5 minutes. The wash buffer and centrifugation 
process was repeated, then 3 x 100uL cell samples were each placed in wash buffer for a 
two hour serum-starve incubation at 37°C. 
 After incubation, one sample was left untreated and insulin (Humulin-R; Lilly 
Pharmaceuticals) was added to the second and third samples in physiological (1.2ng/mL) 
and supra-physiological (12ng/mL) concentrations. These samples were placed in a 37°C 
incubator for five minutes before adipocytes were extracted and snap-frozen in liquid 
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nitrogen for later analysis of insulin signaling by measuring phosphorylated AKT (p-
AKT).  
Whole adipose tissue samples were thawed and combined with a cocktail of 10X 
RIPA (AbCam, Cambridge, MA) and protease inhibitors in a 1:1 sample:cocktail mixture 
before homogenization. Homogenized samples were spun at 1500 x g for 10 minutes, and 
protein extract was isolated from beneath the lipid layer of each sample. Samples were 
analyzed for Hsp27 (Santa Cruz Biotecnology, Santa Cruz, CA), Hsp70 (AbCam, 
Cambridge, MA), Hsp90 (AbCam, Cambridge, MA) and inflammatory markers JNK, p-
JNK, and IKKβ (Santa Cruz Biotechnology, Santa Cruz, CA) using Western Blotting, 
with α-Vinculin (AbCam, Cambridge, MA) used as a loading control. 
Isolated adipocytes were thawed and combined with a 1:1 volume of protease 
inhibitor cocktail for tissue homogenization. Homogenized samples were rotated at 4°C 
for one hour, then spun at 1200 x g for 15 minutes prior to protein subnatant extraction 
and quantification. Analysis of p-AKT was completed using Wes (ProteinSimple, San 
Jose, CA) as previously described (Harris, 2015). 
 The examination of specific HSPs and inflammatory markers was based primarily 
on previous literature linking these HSPs to inflammatory targets and metabolic 
dysfunction (Gupte et al., 2009; Rogers et al., 2015). Insulin signaling can be assessed by 
a variety of downstream targets, and functional outcomes such as GLUT-4 translocation 
or radiolabeled glucose uptake can also be performed. Phosphorylation of AKT was 
selected because it is a critical step in the insulin signaling process, and because the 
PI3K-Akt signaling pathway is known to be disrupted in women with PCOS (Li et al., 
2017). 
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Blood analysis 
 On the morning of each OGTT, additional blood samples were collected for 
baseline analysis of hormonal changes and inflammatory markers. Plasma samples for 
cytokine analysis were collected into EDTA tubes and immediately placed on ice prior to 
centrifugation at 1500 g for 10 minutes at 4°C. Serum samples were collected into serum 
separator tubes and allowed to clot at room temperature prior to following the same 
centrifugation protocol.  
 Serum samples were frozen at -80°C for batch analysis of C-reactive protein 
(Enzo Life Sciences High-Sensitivity Human C-Reactive Protein), total testosterone 
(Enzo Life Sciences High-Sensitivity Testosterone), and Estradiol (Enzo Life Sciences 
High-Sensitivity 17β Estradiol) using commercial enzyme-linked immunosorbent assay 
(ELISA) kits. Samples were diluted 1:4 as suggested and run in duplicate, then calculated 
based on a atandard curve. 
 Plasma samples were frozen at -80°C for batch analysis of inflammatory 
cytokines using a commercial microbead array kit (BD Biosciences Cytometric Bead 
Array, Human Inflammation Panel). Cytometric bead array kits provide antibody or 
antigen-speccific binding sites on beads of varying sizes and/or flourescence, which 
allows for multiplexing assays with a single sample. This kit contained microbead 
specific to IL-1β, IL-6, IL-8, IL-10, IL-12p70, and TNF. Plasma samples were incubated 
overnight with these microbeads to facilitate binding, then read using flow cytometry 
(Beckman-Coulter Gallios). Flow cytometry separates these beads by size, and produces 
a scatter based on the flouresence emitted from bound microbeads. These scatters are 
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then compared to a standard curve of known concentrations of each cytokine, and values 
are calcuated using linear regression from the standard curve from 0 to 5,000pg/mL. 
 
 
 
 
 
In total, these tests of cardiometabolic health, sympathetic activity, and 
inflammation provide a detailed picture of cardiovascular, autonomic, and metabolic 
function, and provide insight into possible mechanisms through which heat therapy could 
improve cardiometabolic health in obese women with PCOS. The techniques and tests 
selected represent a balance between gold-standard measurement techniques and subject 
comfort and time commitment. 
Figure 13 (left). Sample cytokine 
array plot from flow cytometer. 
Cytokine beads are separated by size 
(Y axis) and the scatter along the X 
axis for each analyte is used to 
calculate concentration based on the 
standard curve. 
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CHAPTER IV 
HEAT THERAPY AND VASCULAR HEALTH IN OBESE WOMEN WITH PCOS 
 
Heat exposure has been used for centuries in various populations for purported 
therapeutic benefit, including Scandinavian sauna use, Japanese Waon therapy, Turkish 
baths, and Native American sweat lodges. More recently, repeated passive heat exposure 
(termed ‘heat therapy’) has received renewed interest for improving cardiovascular risk 
profile in healthy populations (Brunt et al., 2016b, 2016c) and those with overt 
cardiovascular disease (Imamura et al., 2001; Kihara et al., 2002; Thomas et al., 2017). 
However, a large spectrum of cardiovascular risk exists between health and disease, and 
populations at an elevated risk of developing cardiovascular disease may have the 
greatest potential benefit of such an intervention.  
Polycystic ovary syndrome (PCOS), an endocrine disorder characterized by 
menstrual dysfunction, clinical hyperandrogenism, and polycystic ovarian morphology 
(Azziz et al., 2006), affects 6-15% of women of child-bearing age and is often 
accompanied by extremely high rates of obesity, insulin resistance, autonomic 
dysfunction (Lansdown & Rees, 2012; Li et al., 2014; Ribiero et al., 2016), and elevated 
markers of inflammation (Escobar-Morreale et al., 2011; Shorakae et al., 2015; Spritzer 
et al., 2015). In combination, these factors substantially elevate cardiovascular risk in 
women with PCOS (Wild et al., 2010). The cardiovascular risk profile includes impaired 
endothelial function (Sprung et al., 2013), increased arterial stiffness (Soares et al., 2009; 
Sasaki et al., 2011), increased wall thickness (Lakhani et al., 2004), and an overall 
increased mortality due to cardiovascular and cerebrovascular events (Rizzo et al., 2009; 
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Wild et al., 2010). Limited pharmaceutical therapies or lifestyle interventions for PCOS 
are specifically aimed at improving cardiovascular health in this population. While 
regular exercise training can improve elements of health including BMI, endocrine 
function, and insulin resistance (Tang et al., 2006; Palomba et al., 2008; Harrison et al., 
2011a) in obese women with PCOS, effects of exercise training on cardiovascular risk 
are less consistent (Harrison et al., 2011a). 
Repeated passive heat exposure (‘heat therapy’), through sauna bathing or regular 
hot tub use, has shown promise in acute and chronic intervention studies as well as 
prospective cohort studies to improve cardiovascular health and reduce risk of mortality 
in various populations. Acute hot water immersion is associated with redistribution of 
blood flow due to cutaneous vasodilation, creating beneficial vascular shear patterns 
(Thomas et al., 2016, 2017) similar to those experienced during exercise (Thomas et al., 
2016), which can promote endothelial cell streaming (Vanbavel, 2007) and reduce plaque 
deposition (Chappell et al., 1998). Acute heat exposure, through hot tub or sauna use, has 
additionally been shown to reduce blood pressure (Boone et al., 1999; Laukkanen et al., 
2017) and improve arterial compliance (Laukkanen et al., 2017; Lee et al., 2018). These 
acute cardiovascular adjustments and functional improvements, with repeated heat 
exposure, may drive the chronic changes observed in long-term heat therapy 
interventions in humans, including reduced arterial blood pressure, reduced wall 
thickness, decreased arterial stiffness, and enhanced endothelial function in the brachial 
artery (Brunt et al., 2016c) and cutaneous microvasculature (Brunt et al., 2016b).  
While changes in vascular function with heat therapy collectively reduce 
cardiovascular risk profile, emerging evidence from large prospective studies indicates 
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that increased frequency and duration of heat (sauna) exposure reduces cardiovascular  
morbidity (risk of incident hypertension (Zaccardi et al., 2017)) and mortality 
(Laukkanen et al., 2015). Fatal cardiovascular events involve blockages to coronary 
(myocardial infarction) or cerebral vasculature (stroke), which lead to tissue 
ischemia/reperfusion (IR) injury. In murine models, 30-day heat acclimation affords 
protection from IR injury, such that cardiac myocytes are better able to survive IR stress 
(Maloyan et al., 2005). In humans, acute hot tub use appears to temporarily protect tissue 
from IR stress (Brunt et al., 2016d), but this effect has not been examined in a chronic 
heat intervention. This protection would be particularly powerful in obese women with 
PCOS, a population with increased risk of cardiovascular or cerebrovascular death. 
Therefore, the purpose of this study was to examine the effect of a 30-session heat 
therapy intervention on arterial stiffness, arterial wall thickness, endothelial function, and 
vascular tolerance to ischemia-reperfusion in obese women with PCOS. Based on the 
results of Brunt et al. (Brunt et al., 2016c), we hypothesized that a 30-session heat 
therapy intervention in obese women with PCOS would decrease arterial wall thickness 
and stiffness, increase endothelial function (assessed by flow-mediated dilation; FMD), 
and reduce the impairment in FMD following IR stress. 
 
Methods 
Subjects. Eighteen obese women (defined as a BMI ≥30 and ≤45) volunteered to 
participate in this study. All subjects were non-smokers and had not been diagnosed with 
overt cardiovascular disease or diabetes. All women had to be diagnosed with PCOS by a 
physician and based on the Rotterdam criteria (clinical hyperandrogenism, menstrual 
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dysfunction, and/or presence of ovarian cysts upon ultrasound examination) qualify for 
inclusion. Women were matched for age and BMI and placed in either the heat therapy 
intervention (HT) or time control (CON; no heat exposure) group. A summary of 
physical characteristics is listed in Table 2. Using the 2017 American Heart Association 
guidelines for hypertension, seven subjects (3 HT, 4 CON) were classified as “elevated 
blood pressure”, and seven were classified as Stage 1 Hypertensive (4 HT, 3 CON). Two 
subjects in each group were classified as normotensive (systolic [SBP] <120 and diastolic 
[DBP] <80 mmHg). 
 
 All Subjects (n=18) HT (n=9) CON (n=9) 
Age (years) 27 ± 1 26 ± 2 27 ± 2 
BMI 41.3 ± 1.1 41.8 ± 1.4 40.7 ± 1.9 
Waist:Hip Ratio 0.85 ± 0.01 0.85 ± 0.01 0.86 ± 0.02 
Blood Pressure (mmHg)    
   SBP 123 ± 2 124 ± 2 123 ± 3 
   DBP 76 ± 1 77 ± 2 75 ± 2 
   MAP 92 ± 1 93 ± 1 91 ± 2 
 
 
Heat Therapy Intervention. Heat therapy occurred over an eight to ten week 
period, with a total of 30 x one hour sessions scheduled three to four per week in all 
Table 2. Summary of physical characteristics and baseline blood pressure in all 
vascular function subjects, heat therapy (HT) and control (CON). 
 61 
 
subjects enrolled in the HT group (control subjects were not exposed to heat, but 
completed all testing at matched timepoints [Pre, Mid, Post]). This exposure duration and 
timeline was selected based on previous work in our lab, where promising improvements 
in vascular health were seen over an 8-week, 36 session heat therapy intervention (Brunt 
et al., 2016c). The acute exposure duration and total number of sessions were reduced 
slightly from our previous heat therapy work in order to create an intervention more 
similar in time commitment to exercise training protocols performed in women with 
PCOS (Harrison et al., 2011a). Passive hot water immersion was selected as the method 
of heat stress because it is capable of increasing core temperature at a rate similar to 
moderate-intensity exercise (Kenny et al., 1996), while also producing high skin 
temperature and sweating rate, all requisite components for adaptation to heat (Fox et al., 
1963; Buono et al., 2009). 
 
Subjects reported to the laboratory to undergo passive heating, which entailed 60 
min of water immersion in a bath set to 40.5°C. Previous research in our laboratory 
suggests this water temperature will raise core temperature ≥ 38.5°C within 20-30 
minutes. This threshold was selected based on human heat acclimation literature using 
isothermic models (Fox et al., 1963), and is additionally important as a threshold for 
induction of heat shock proteins (Taylor, 2014). Once core temperature rose to 38.5°C, 
subjects sat upright (immersed to the waist) for the remainder of the one hour session in 
order to maintain core temperature between 38.5-39.0°C. If temperature dropped below 
38.5, subjects were asked to submerge again. After 60 minutes of exposure, subjects were 
asked to sit next to the tub until core temperature fell below 38.5˚C (10-15 minutes) for 
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safety monitoring, and for monitoring the total exposure duration where core temperature 
was above 38.5°C.  
Upon arrival, subjects provided a urine sample for measurement of specific 
gravity (USG) to confirm euhydration (USG ≤ 1.02) prior to heat exposure. Subjects 
were also weighed pre- and post-heat exposure (nude, towel-dried, behind a privacy 
screen) and given water to drink ad libitum during heat exposure and post-heat exposure 
if necessary to match fluid losses. Heart rate was monitored throughout heating using 
commercially-available heart rate monitors (Polar Electro, New York, NY), while rectal 
temperature (Tre) was monitored throughout passive heating by rectal thermistor (YSI, 
Yellow Springs, OH).  
Vascular Function. Vascular function study days took place at the start of testing 
(Pre), after 4-5 weeks (Mid; 15 heat therapy sessions or matched time control), and at the 
conclusion of heat therapy (Post; 8-10 weeks, 30 sessions, or equivalent time control), 
24-72 hours after the most recent heat exposure in HT subjects. All subjects reported to a 
thermoneutral lab environment, having refrained from food for a minimum of four hours, 
caffeine and alcohol for 12 hours, vitamin supplementation, medications (other than oral 
contraceptive) and exercise for at least 24 hours. Time of day was held constant (within 1 
hr) for each subject over time in order to minimize circadian influence. Body mass and 
height were measured, and a urine sample was collected for confirmation that the subject 
was not pregnant prior to beginning testing. Subjects rested on a padded exam table for a 
minimum of 20 minutes prior to beginning testing, and during this time they were 
instrumented with a 3-lead ECG, brachial blood pressure cuff, and beat-by-beat blood 
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pressure monitor (Nexfin, Edwards Life Sciences, Irvine, CA). Testing order was held 
constant, beginning with assessment of common carotid wall thickness and dynamic 
arterial compliance (DAC), followed by superficial femoral wall thickness and DAC, 
Carotid-Femoral and Brachial-Ankle pulse wave velocity, and flow-mediated dilation 
(FMD) before and after ischemia-reperfusion. 
Wall thickness. Wall thickness of the common carotid and superficial femoral 
artery were imaged using high-resolution Doppler ultrasound (Terason t3000cv; 
Teratech, Burlington, MA, USA) in B mode with 10.0 MHz linear array ultrasound 
transducer probe artery. The carotid artery was imaged 2 cm distal to the carotid bulb at 
three angles: anterior, lateral and posterior. The superficial femoral artery was imaged 2–
4 cm distal to the femoral bifurcation in two planes: anterior and lateral. Clearly 
distinguished intimal–medial boundaries were obtained on the far wall. Images were 
frozen in diastole and enlarged, and calipers were used to make three repeat 
measurements of the wall thickness from the lumen–intima interface to the media–
adventitia interface. Video recording of these measurements was later reviewed offline to 
confirm accuracy of caliper measurement, and three measurements from each angle were 
averaged. 
Arterial Stiffness. Arterial stiffness was assessed using several different methods, 
including carotid and superficial femoral dynamic arterial compliance (DAC), and 
carotid-femoral and brachial-ankle pulse wave velocity (PWV). Carotid and femoral 
DAC were measured using high-resolution Doppler ultrasound (Terason t3000cv; 
Teratech, Burlington, MA, USA) with 10.0 MHz linear array ultrasound transducer probe 
with concurrent applanation tonometry (PCU-2000; Millar, Inc., Houston, TX, USA) on 
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the same artery on the contralateral side of the body. Ultrasound probe placement on the 
body, including angle of approach and internal anchors such as distance from bifurcation, 
were recorded on the first trial day and repeated to ensure consistency between repeated 
measurements over the course of the study. All ultrasound recordings were performed on 
the right side of the body. Ultrasound images were recorded at 20 Hz using video 
recording software (Camtasia), then analyzed for diameter and blood velocity using 
custom-designed edge detection and wall tracking software (DICOM; Perth, Australia). 
Pulse pressure using applanation tonometry was simultaneously recoded via WinDaq data 
acquisition (Dataq, Inc) at 250 Hz, and analyzed using the trough to peak pressure 
differential. This pressure differential (∆P) was then analyzed relative to change in 
diameter (∆D) for a minimum of 50 cardiac cycles in order to calculate cross-sectional 
compliance and β stiffness using the following equations: 
Dynamic arterial compliance = [(∆D/D)/2∆P] * πD2 
Β-stiffness index = Ln (SBP/DBP)*D/∆D 
Pulse wave velocity was assessed using tonometry probes placed on the carotid & 
femoral arteries (central PWV or aortic stiffness), as well as the brachial and dorsal pedal 
arteries (peripheral PWV).  Tracings were recorded using data acquisition software 
(WinDaq; Dataq Instruments, Akron, OH, USA), and the pulse upswings of a minimum 
of thirty simultaneously recorded pressure tracings were identified offline by a blinded 
investigator in order to calculate the time differential. Velocity was calculated as distance 
over time, where distance was the sum of the linear distances between the carotid probe 
and the sternal notch and the sternal notch to the femoral probe, or the distance 
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differential between the brachial probe to sternal notch and the ankle probe to sternal 
notch.  
Flow-mediated Dilation with Ischemia/Reperfusion. Endothelial function was 
assessed using flow-mediated dilation (FMD) at the brachial artery using Doppler 
ultrasonography. On each study day, FMD was measured at baseline and again after a 20 
minute occlusion-20 minute reperfusion as a model of endothelial function in response to 
an acute IR episode. FMD consists of imaging of the brachial artery by Doppler 
ultrasound to obtain baseline diameter and blood velocity measurement, then inflating an 
occlusion cuff (set to 250 mmHg) just below the elbow for a period of 5 minutes. 
Velocity and diameter were captured using Doppler ultrasound, and the ultrasound 
images were recorded (Camtasia software) and analyzed for changes in brachial artery 
diameter and blood velocity after cuff release. FMD at the brachial artery has been shown 
to parallel coronary artery endothelial function (Teragawa et al., 2005), is a well-
established predictor of cardiovascular risk and future cardiovascular events (Yeboah et 
al., 2008; Shechter et al., 2009), and has improved with heat therapy  in healthy humans 
(Brunt et al., 2016c). In addition, FMD is impaired by IR (Seeger et al., 2015; Brunt et 
al., 2016d). IR was performed by placing an occlusion cuff on the upper arm (above the 
point where the brachial artery was imaged for FMD) and inflating it to 250mmHg for a 
period of 20 minutes. Twenty minutes after release of the cuff, FMD was re-assessed. 
This protocol was selected as it has been used in acute exercise (Seeger et al., 2015) and 
heat (Brunt et al., 2016d) interventions, has been well-tolerated by subjects, and shows a 
short-term impairment of endothelial and microvascular function. 
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Fasting Blood Lipids and C-Reactive Protein. On a separate day at each timepoint 
(Pre-Mid-Post), subjects reported to the lab after a 12-hr overnight fast, having refrained 
from medications, exercise, and heat exposure for ≥24 hours, for a venous blood draw. 
Blood was drawn from the antecubital space into serum separator tubes, then allowed to 
clot at room temperature for 30 minutes prior to centrifugation (10 minutes at 1500 x g at 
4°C). Serum was frozen at -80°C and later thawed for analysis of C-reactive protein 
(Enzo Life Sciences) and cholesterol panels (OHSU lipid lab, Portland, OR). 
Statistics. All data are presented as mean ± SEM. Results were analyzed using 
mixed-model ANOVA in GraphPad Prism 6, with repeated measures within HT or CON 
groups for each subject, and non-repeated measures comparison between groups of 
subjects. If a significant main effect was observed, Holm-Sidak post-hoc analysis was 
utilized to examine within- or between-group effects. 
 
Results 
Nine HT subjects completed the heat intervention, and eight subjects completed 
the time control (one CON subject withdrew after completing Pre testing, and was 
therefore excluded from analysis). All experimental subject completed 30 heat therapy 
sessions over 8-10 weeks. Sessions were scheduled at the subject’s convenience, with the 
first (session 1) and last session (session 30) scheduled at the same time of day in order to 
examine variables related to heat adaptation that are sensitive to circadian influence. A 
significant reduction in baseline heart rate and core temperature (measured seated in 
thermoneutral room, prior to hot water immersion) and increase in sweating rate during 
heating were evident in the final session (Table 3). 
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Table 3. Baseline heart rate, core temperature, and sweating rate in the first (session 1) and 
last (session 30) heat therapy day. 
 
 
 
Wall Thickness. As seen in figure 14, both common carotid and superficial 
femoral wall thickness decreased, with femoral artery wall thickness decreasing by the 
mid timepoint, and carotid decreasing at the end of 8-10 weeks (30 heat sessions; Post).  
 Session 1 Session 30 P value 
Baseline Heart Rate 
(BPM) 
113 ± 2 98 ± 3 0.003 
Baseline Tre (°C) 37.6 ± 0.1 37.2 ± 0.1 0.0003 
Sweating Rate (L/hr) 0.71 ± 0.06 1.21 ± 0.06 <0.0001 
    
Figure 14. Common carotid and superficial femoral wall thickness over time in heat 
therapy (HT) and control (CON) subjects. * Denotes significant different from Pre 
timepoint. 
 
 68 
 
Arterial Stiffness. Cross-sectional compliance and β-stiffness for the common 
carotid and superficial femoral artery are shown in Figure 15. Βeta stiffness did not 
change in either the carotid or femoral artery; however; a decrease in carotid compliance 
occurred at the end of HT in experimental subjects. Brachial-ankle PWV decreased at the 
Post timepoint in experimental subjects, while carotid-femoral PWV did not change 
(Table 4). Systolic, diastolic, and mean arterial pressure decreased in experimental 
subjects throughout the 8 weeks, with an average decrease of 10mmHg (Table 4). 
 
Blood lipids and C-reactive protein. C-reactive protein levels were classified as 
‘moderate risk’ in both groups, and significantly decreased in HT subjects in Mid 
(p=0.033) and Post testing (p=0.038), with no change in CON over time (Table 4).  
Figure 15. Common carotid and superficial femoral DAC and β stiffness index over time 
in heat therapy (HT) and control (CON) subjects. * Denotes significant different from Pre 
timepoint. 
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  Pre Mid Post 
 
BMI   
(kg/m2) 
 
HT 
CON 
 
41.8 ± 1.4 
39.9 ± 1.9 
 
41.9 ± 1.4 
39.8 ± 1.8 
 
41.8 ± 1.5 
39.5 ± 1.8 
C-Reactive Protein 
(mg/L) 
HT 
CON 
2.03 ± 0.49 
1.92 ± 0.53 
1.55 ± 0.35* 
2.16 ± 0.67 
1.63 ± 0.45* 
2.13 ± 0.67 
SBP  
(mmHg) 
HT 
CON 
124 ± 2 
122 ± 3 
119 ± 2 
124 ± 2 
114 ± 2* 
120 ± 2 
DBP 
 (mmHg) 
HT 
CON 
77 ± 2 
74 ± 2 
69 ± 4* 
73 ± 2 
68 ± 1* 
75 ± 2 
MAP  
(mmHg) 
HT 
CON 
93 ± 1 
90 ± 2 
86 ± 3* 
90 ± 2 
83 ± 1* 
90 ± 2 
Carotid-Femoral PWV 
(cm/sec) 
HT 
CON 
698 ± 23 
697± 59 
711 ± 43 
690 ± 42 
689 ± 15 
680 ± 38 
Brachial-Ankle PWV 
(cm/sec) 
HT 
CON 
870 ± 27 
869 ± 43 
844 ± 42 
841 ± 54 
798 ± 24* 
845 ± 41 
Brachial Artery 
Diameter (cm) 
HT 
CON 
0.315 ± 0.025 
0.302 ± 0.029 
0.326 ± 0.024* 
0.304 ± 0.030 
0.337 ± 0.022* 
0.306 ± 0.026 
     
Table 4. BMI, C-reactive protein, blood pressure, PWV, and brachial diameter over time 
in heat therapy (HT) and control (CON) subjects. * Denotes significantly different from 
Pre timepoint. 
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Pre-IR FMD. FMD, expressed as a percent change in brachial artery diameter, did 
not change in HT or CON subjects over time (Figure 16). However, HT subjects 
experienced a significant increase in baseline diameter at Mid and Post (Table 4), so that 
when FMD was corrected for shear rate, an increase in FMD was seen at the Mid and 
Post timepoint. No changes in FMD were seen in CON subjects in absolute % dilation or 
shear-corrected FMD.  
 
Figure 4. FMD (%) and shear-corrected FMD over time in heat therapy and control  
subjects. * Denotes significant different from Pre timepoint. 
 
Figure 17. FMD before (Pre-IR) and after (Post-IR) IR in heat therapy (HT) and control 
(CON) subjects. * Denotes significant difference from Post-IR at Pre timepoint. 
Figure 16. FMD (%) and shear-corrected FMD over time in heat therapy and control 
subjects.  
* Denotes significant difference from Post-IR at Pre timepoint. 
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Post-IR FMD. FMD was significantly decreased, albeit variably, by IR at the Pre 
timepoint in both groups (Figure 17). However, in HT subjects, post-IR FMD 
significantly increased at the Mid and Post timepoints so that FMD was preserved (no 
impairment from IR) in Post testing. 
 
Discussion 
 
The cardiovascular risk profile of obese women with PCOS has been well-
described; however; relatively few pharmaceutical or lifestyle interventions for women 
with PCOS address cardiovascular risk reduction. Based on our results, heat therapy 
appears to be a promising intervention to reduce cardiovascular risk in this population. 
Specifically, our primary findings indicate that a 30-session heat therapy intervention: 1) 
promoted reductions in carotid and femoral wall thickness 2) reduced serum C-reactive 
protein 3) increased carotid compliance and BA-PWV 3) improved endothelial function 
as assessed by FMD and 4) protected endothelial function from IR-related impairments in 
obese women with PCOS. As described in previous work (Brunt et al., 2016c) and recent 
reviews (Ely et al., 2018), there are multiple possible mechanisms for the observed 
improvements in vascular function, including hemodynamic adjustments during acute 
heat, increased abundance of heat shock proteins, and potential neurovascular changes. 
PCOS, especially when accompanied by obesity, is associated with a meta-
inflammatory state (Shorakae et al., 2015) and dyslipidemia (Diamanti-Kandarakis et al., 
2007). In combination, these factors can lead to accelerated plaque deposition on arterial 
walls, and increased wall thickness observed in obesity and PCOS (Meyer et al., 2012; 
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Allameh et al., 2013). In PCOS, hyperinsulinemia, elevated blood pressure, and high 
serum testosterone can additionally influence plaque deposition and arterial wall 
thickening. Exercise training protocols produce similar changes in carotid wall thickness 
in obese women with PCOS (Orio et al., 2016), and the magnitude of change in carotid 
wall thickness is on par with what has been observed in similar heat therapy interventions 
in healthy, sedentary humans (Brunt et al., 2016c). However, the large and clinically 
relevant change in superficial femoral wall thickness has not been observed in healthy 
humans undergoing heat therapy (Brunt et al., 2016c), and has not been assessed in obese 
women with PCOS following exercise training. Since arterial thickening can be related to 
inflammation (Chang et al., 2017), oxidative stress, and blood pressure (Oren et al., 
2003), it is possible that the higher level of baseline inflammation and dysfunction in 
obese women with PCOS, combined with a dramatic decrease in blood pressure, allowed 
for a larger effect of heat therapy to be observed compared to healthy, inactive humans 
(Brunt et al., 2016c). It is also possible that healthy humans have a ‘basement effect’ on 
some cardiovascular parameters, making further improvement in already healthy blood 
vessels difficult to achieve. In support of this, superficial femoral wall thickness measures 
at the end of heat therapy were still higher in obese women with PCOS than those 
observed at the start of heat therapy in healthy individuals (Brunt et al., 2016c). 
Arterial wall thickening and plaque deposition is a process driven by 
hyperlipidemia, inflammation, and oxidative stress. C-reactive protein is released by the 
liver in response to pro-inflammatory cytokines and adipokines (Yudkin et al., 1999), and 
is considered a global inflammatory marker that is highly associated with various markers 
of cardiovascular health (Wilson et al., 2008). C-reactive protein levels are stratified as 
 73 
 
<1 mg/L (low risk), 1-3 mg/L (average risk), and >3mg/L (high risk) (Ridker et al., 
2002). Subjects in this study displayed serum C-reactive protein in the moderate range, 
which was expected based on previous work in obese women with PCOS (Escobar-
Morreale et al., 2011; Spritzer et al., 2015). C-reactive protein has not previously been 
examined in heat therapy interventions; however; frequency of sauna use was inversely 
associated with C-reactive protein in a prospective cohort study in men (Laukkanen & 
Laukkanen, 2018). In addition, animal models have observed reductions in inflammatory 
cytokines including IL-6 and TNFα in response to heat (Kim et al., 2005), and C-reactive 
protein production is influenced by changes in systemic inflammation, so a change in 
circulating pro-inflammatory cytokines in response to heat could explain the HT-induced 
reduction in C-reactive protein in obese women with PCOS. The magnitude of 
improvement we observed in HT was not large enough to alter risk category; however; it 
indicates that heat therapy is reducing systemic inflammation, which likely contributes to 
observed reductions in wall thickness, arterial stiffness, and enhanced endothelial 
function. 
In healthy humans, chronic heat therapy reduced measures of arterial stiffness, 
including superficial femoral compliance and β-stiffness, and aortic (carotid-femoral) 
pulse wave velocity (Brunt et al., 2016c). In obese women with PCOS, heat therapy 
increased common carotid compliance and reduced brachial-ankle PWV, with no 
significant impact on femoral compliance, β-stiffness, or aortic PWV. As the β-stiffness 
index is less influenced by blood pressure changes than cross sectional compliance 
measures, it is likely that a decrease in blood pressure, rather than a change in structural 
properties of the artery, explained the increase in common carotid artery compliance. 
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Similarly, due to the inclusion of resistance vessels, brachial-ankle PWV is more 
sensitive to changes in autonomic influence and vascular tone than carotid-femoral PWV, 
so these results may again indicate an overall decrease in blood pressure and baseline 
vascular tone rather than structural arterial remodeling. It is worth noting that BMI and 
waist circumference (central obesity) are both associated with increased aortic stiffness 
(Safar et al., 2006; Ketel et al., 2010; Strasser et al., 2015; van den Munckhof et al., 
2017), and the high BMI and central obesity that persisted through the HT intervention 
could be driving central arterial stiffness in this subject population. It is also possible that 
30 1-hr heat therapy sessions over 8-10 weeks are not sufficient to create significant 
arterial remodeling in a population with multiple contributing risk factors (obesity, 
hyperinsulinemia, androgen excess, elevated blood pressure). It is also possible that with 
the large variation in magnitude of response and the spectrum of baseline dysfunction in 
obese women with PCOS did not allow for consistent, significant, and clinically 
meaningful changes in arterial stiffness in this subject population and sample size.  
Clinically meaningful changes in endothelial function were present by the mid-
point of HT in experimental subjects, and further increased by the end of heat therapy. 
FMD is a well-described measure of endothelial function (Atkinson et al., 2013) and 
strong clinical correlate of cardiovascular risk (Yeboah et al., 2008; Shechter et al., 
2009), with a 2% improvement in FMD representing a 15% improvement in 
cardiovascular risk (Shechter et al., 2009). The ~3% change in shear-corrected FMD over 
the heat therapy intervention is smaller than observed in healthy humans undergoing a 
similar protocol (Brunt et al., 2016c), but more robust than the change in FMD observed 
in overweight women with PCOS following 10-26 weeks of exercise training 
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(Almenning et al., 2015; Orio et al., 2016). While FMD is not exclusively dependent 
upon nitric oxide (Wray et al., 2013), heat therapy-mediated increases in NO 
bioavailability as observed over the course of heat therapy in previous work (Brunt et al., 
2016b) are likely predominantly responsible for increases in FMD in obese women with 
PCOS over HT. 
The effect of heat therapy on FMD after IR stress was even more pronounced than 
at baseline (Pre-IR), approaching a 4% increase, and, more importantly, heat therapy 
preserved FMD following IR stress by the end of 8-10 weeks. While this experimental 
model may be difficult to translate to true IR tissue injury, these data support the effect 
observed in isolated rat hearts following a 30 day heat acclimation protocol (Maloyan et 
al., 2005), and offer a potential explanation for the reduction in fatal cardiovascular 
events seen with increased sauna use in men (Laukkanen et al., 2015). It is possible that 
this protection is related to increased abundance of cytoprotective heat shock proteins, as 
seen in isolated rat heart models (Maloyan et al., 2005; Horowitz & Assadi, 2010). It is 
also possible, given that IR injury is primarily due to high oxidative stress during 
reperfusion (Kaminski et al., 2002), that heat therapy confers protection from oxidative 
stress as seen in human exercise-heat acclimation (Kaldur et al., 2014). 
In summary, a 30-session heat therapy intervention leads to robust improvements 
in cardiovascular risk in obese women with PCOS. The reductions in blood pressure, wall 
thickness, arterial stiffness, and improved endothelial function are similar to or greater 
than those seen with exercise training and/or diet interventions in women with PCOS. 
Moreover, these changes occurred without any change in BMI (Table 4), indicating that 
heat therapy used in combination with diet or exercise interventions that lead to weight 
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loss may provide an additive benefit through mechanisms unrelated to changes in body 
mass. These data support previous work examining heat therapy and cardiovascular 
health (Imamura et al., 2001; Brunt et al., 2016c), and additionally indicate that heat 
therapy can reduce inflammation and provide protection from IR injury in populations 
with an elevated cardiovascular morbidity and mortality. In combination, the magnitude 
and breadth of changes observed in this study dramatically reduce the cardiovascular risk 
profile in obese women with PCOS. 
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CHAPTER V 
HEAT THERAPY AND AUTONOMIC ACTIVITY IN OBESE WOMEN WITH PCOS 
 
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder characterized 
by androgen excess, menstrual dysfunction, and the appearance of cysts on the ovaries. 
While this syndrome affects 5-18% of women of child-bearing age and has various 
associated health risks including obesity, insulin resistance, and hypertension (Luque-
Ramírez & Escobar-Morreale, 2014), the pathophysiology of PCOS is still poorly 
understood and potential treatments to ameliorate the health risk profile in these women 
deserve further study. One particular target requiring further study is the sympathetic 
nervous system, both as a potential driver of ovarian dysfunction (Aguado, 2002) and 
associated cardiometabolic dysfunction (Di Domenico et al., 2013) in PCOS, and as a 
potential therapeutic target (Lansdown & Rees, 2012). Women with PCOS have elevated 
muscle sympathetic nerve activity (MSNA) (Sverrisdottir et al., 2008; Li et al., 2014). 
Similarly, measurement of heart rate variability (HRV) as an estimate of cardiac 
parasympathetic and sympathetic influence suggests elevated sympathetic tone and low 
parasympathetic tone in PCOS (De Sá et al., 2011; Di Domenico et al., 2013; Hashim et 
al., 2015; Ribiero et al., 2016). Limited research has examined treatments targeting the 
sympathetic nervous system in PCOS, with pharmacological treatment using 
Moxonidine, a central inhibitor of sympathetic outflow acting in the rostral ventrolateral 
medulla showing no effect on MSNA, HRV, or endothelial function in PCOS women 
(Shorakae et al., 2017). The only effective interventions for reducing MSNA in PCOS 
have been exercise training and electroacupuncture (Stener-Victorin et al., 2009), both of 
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which reduced MSNA but, somewhat surprisingly, did not contribute to a healthier 
cardiovascular risk profile. Chronic passive heat exposure (termed ‘heat therapy’) offers 
promise as a novel therapy to alter autonomic outflow, potentially reducing MSNA and 
increasing HRV in women with PCOS. 
To date, research on heat therapy and autonomic function is extremely limited in 
humans. The only evidence in humans on heat adaptation influencing resting MSNA is 
inferred from seasonal variation studies, with an observed decrease in MSNA in summer 
compared with winter potentially attributed by the authors to warmer environmental 
temperature (Niimi et al., 1999; Cui et al., 2015). In rodent models, passive heat 
acclimation was associated with increased parasympathic and decreased sympathetic 
influence on autorhythmic cells, as measured by infusion of atropine and propranolol 
(Horowitz & Meiri, 1993), although sympathetic nerve activity was not directly assessed. 
Sympathetic nerve activity in obesity and PCOS is influenced by a multitude of factors, 
including hyperinsulinemia, inflammatory cytokines, adipokines, hormonal factors, and 
other bioactive molecules such as nitric oxide. Nitric oxide (NO) production or 
bioavailability in cutaneous microcirculation increases in human heat therapy (Brunt et 
al., 2016b), and if heat therapy results in similar increases in neuronal NO release or 
bioavailability in the central nervous system, this would lead to a reduction in central 
sympathetic outflow. While there is some evidence of altered insulin sensitivity (Gupte et 
al., 2009), inflammatory cytokine production (Kim et al., 2005), and adipokine secretion 
in animal models of heat exposure (Morera et al., 2012), most other mediators of 
sympathetic outflow have not been examined in human heat therapy models.  
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Heat acclimation studies in humans have examined plasma (Nielsen et al., 1993, 
1997; Febbraio et al., 1994) or urinary (Maher et al., 1972) norepinephrine 
concentrations immediately after acute exercise-heat stress and noted a decline following 
an exercise-heat acclimation protocol, indicating reduced sympathetic activity during 
acute exercise-heat exposure as a result of heat acclimation. However; this response may 
be specific to the stress (acute exercise) and the acclimation model (exercise-heat 
exposure) employed. Similarly, heart rate variability has been assessed following 
exercise-heat acclimation in healthy individuals (Frank et al., 2001; Epstein et al., 2010; 
Flouris et al., 2014) but again measurements were only made in the heat and/or during 
exercise, and the studies achieved disparate results, with two reporting increased 
variability (increased parasympathetic activity) (Epstein et al., 2010; Flouris et al., 2014) 
and one reporting an increase in sympathetic tone (Frank et al., 2001) following heat 
acclimation. No study to date, in the human or animal literature, has examined resting 
muscle sympathetic nerve activity after a long-term heat intervention. This is particularly 
important to examine in a clinical population with high sympathetic activity, such as 
obese women with PCOS. 
Therefore, the purpose of this study was to examine muscle sympathetic nerve 
activity in obese women with PCOS over the course of 30 session, 8-10 week heat 
therapy intervention, and to examine blood parameters including serum insulin, 
testosterone, inflammatory cytokines, and adipokines that might contribute to changes in 
MSNA. A secondary purpose was to examine heart rate variability over the same time as 
a supplemental index of autonomic function. We hypothesized that baseline MSNA 
would decline following the chronic heat intervention, and that indices of heart rate 
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variability would increase, suggesting a decrease in sympathetic and increase in 
parasympathetic tone.  
 
Methods 
Eighteen obese women (body mass index; BMI 30-45) were enrolled in this 
study. All subjects completed a health screening visit prior to enrollment to ensure they 
met all inclusion criteria. All subjects were diagnosed with Polycystic Ovary Syndrome 
by their primary care physician and met the Rotterdam Criteria (menstrual dysfunction, 
hyperandrogenism, and/or ovarian cysts)(Rotterdam ESHRE/ASRM-Sponsored PCOS 
consensus workshop group, 2004). Subjects were non-smokers and did not have any 
overt cardiovascular disease or diabetes. These women were matched for age and BMI, 
and assigned to either heat therapy (HT) or time control (CON) groups. The goal was to 
recruit subjects who were not taking any medications; however; the extremely high 
prescription rates in PCOS made this difficult. In total, one subject in each group was 
taking oral contraceptives (OC), and two subjects in each group were taking selective 
serotonin reuptake inhibitors (SSRI) for treatment of depression or anxiety, both common 
in PCOS (Deeks et al., 2010). While these medications can potentially influence 
autonomic outflow, medication rates were matched between groups, and subjects were 
taking the medication at a consistent dose and time of day throughout the study. 
Demographic data for all subjects are presented in Table 5. 
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 All Subjects (n=18) HT (n=9) CON (n=9) 
Age 27 ± 1 26 ± 2 27 ± 2 
BMI 41.3 ± 1.1 41.8 ± 1.4 40.7 ± 1.9 
Waist:Hip Ratio 0.85 ± 0.01 0.85 ± 0.01 0.86 ± 0.02 
Blood Pressure    
   SBP 123 ± 2 124 ± 2 123 ± 3 
   DBP 76 ± 1 77 ± 2 75 ± 2 
   MAP 
Medications 
92 ± 1 93 ± 1 91 ± 2 
 
 N=2 OCs 
N=4 SSRI 
N=1 OC 
N=2 SSRI 
N=1 OC 
N=2 SSRI 
 
Heat Therapy Intervention. Heat therapy occurred over an eight to ten week 
period, with a total of 30 x one hour sessions scheduled three to four per week in all 
subjects enrolled in the experimental group (control subjects were not exposed to heat). 
The acute exposure duration and total number of sessions was selected because it is 
similar in time commitment to exercise training protocols performed in women with 
PCOS (Harrison et al., 2011a). For each session, subjects reported to the laboratory to 
undergo 60 min of water immersion in a bath set to 40.5°C. Previous research in our 
laboratory suggests this temperature is optimal to raise core temperature ≥ 38.5°C within 
20-30 minutes. Once core temperature rose to 38.5°C, subjects sat upright (immersed to 
Table 5. A summary of demographic characteristics, including age, BMI, blood 
pressure, and medications in HT and CON subjects. 
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the waist) for the remainder of the one hour session in order to maintain core temperature 
between 38.5-39.0°C. If temperature dropped below 38.5, subjects were asked to 
submerge again. After 60 minutes of exposure, subjects were asked to sit next to the tub 
until core temperature fell below 38.5˚C (10-15 minutes) for safety monitoring, and for 
monitoring the total exposure duration where core temperature was above 38.5°C. This 
threshold was selected based on human heat acclimation literature using isothermic 
models (Fox et al., 1963), and is additionally important as a threshold for induction of 
heat shock proteins (Taylor, 2014), which may contribute to changes in sympathetic 
activity through their role in enhancing NO signaling (Pritchard et al., 2001; Bharati et 
al., 2017), reducing inflammatory cytokines (Dokladny et al., 2010), and increasing 
insulin sensitivity (Gupte et al., 2009). 
Upon arrival, subjects provided a urine sample for measurement of specific 
gravity (USG) to confirm euhydration (USG ≤ 1.02) prior to heat exposure. Subjects 
were also weighed pre- and post-heat exposure (nude, towel-dried, behind a privacy 
screen) and given water to drink ad libitum during heat exposure and post-heat exposure 
if necessary to match fluid losses. Heart rate was monitored throughout heating using 
commercially-available heart rate monitors (Polar Electro, New York, NY), while rectal 
temperature (Tre) was monitored throughout passive heating by rectal thermistor (YSI, 
Yellow Springs, OH).  
Muscle sympathetic nerve activity (MSNA). MSNA was recorded via 
microneurography of the peroneal nerve (Sundlöf & Wallin, 1977; Wallin & Sundlof, 
1979) at the beginning (0 heating sessions), mid-point (after 14-16 heating sessions, or a 
similar 4-5 week time interval in control subjects) and end (after 30 heat sessions or 
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equivalent time control). All testing took place in a thermoneutral (18-21°C) room, 24-72 
hours after the most recent heat session in an attempt to isolate chronic, rather than acute, 
effects of heat. Briefly, the nerve was located using external stimulation in the region 
behind the knee and below the fibular head, and sites that showed strong muscle twitches 
were marked for reference. Once a site was selected, post-ganglionic MSNA was 
recorded through a tungsten microelectrode inserted percutaneously into the peroneal 
nerve. Nerve traffic was recorded continuously at 250 Hz and analyzed using standard 
techniques as described previously (Halliwill, 2000) at baseline (quiet supine resting with 
and without paced breathing to a metronome). MSNA was recorded using Windaq data 
acquisition software with simultaneous recording of EKG and beat-by-beat blood 
pressure (Nexfin). Sympathetic nerve bursts were identified offline by two investigators 
(one blinded) with a minimum 3:1 signal: noise ratio and confirmed by measuring pulse 
synchronicity. Primary variables of interest for MSNA were burst frequency (bursts/min; 
measured over a minimum of five minutes) and burst incidence (bursts/100 heartbeats; 
measured over a minimum of 5 minutes). 
Sympathetic baroreflex sensitivity was assessed by having subjects perform a 
Valsalva maneuver during MSNA. This was accomplished using an expiratory pressure 
gauge with an on-screen display of pressure. Subjects were encouraged to maintain 
pressure at 40mmHg for 20 seconds while contracting their abdominals and avoiding 
muscle contraction in other parts of the body. Sympathetic baroreflex sensitivity was 
examined by locating the diastolic pressure nadir (5 consecutive cardiac cycles with 
pressure dropping during Phase II) and examining change in diastolic pressure and burst 
incidence during this period. By plotting diastolic pressure and burst incidence at rest 
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compared with during Phase II nadir, a slope (∆BI/∆DBP) was calculated as a measure of 
baroreflex sensitivity. This assessment of sympathetic baroreflex sensitivity during 
Valsalva is well correlated with measures of spontaneous baroreflex sensitivity (Yang & 
Carter, 2013). 
Heart Rate Variability. Due to difficulty in obtaining nerve tracings in some 
subjects, we additionally assessed autonomic function using heart rate variability at rest 
and during paced breathing in all subjects. Spectral analysis heart rate variability is a 
widely-used, non-invasive, estimate of autonomic influence on the heart. While its 
correlation with MSNA and cardiac NE spillover is poor (Kingwell et al., 1994) in 
clinical populations, measures of low-frequency variability (LFnu; attributed to high 
sympathetic activity) do track with MSNA in healthy individuals in select conditions 
(DeBeck et al., 2010). In addition, overall variability and high-frequency variability 
(HFnu; attributed to parasympathetic activity) appear to be decreased, indicating 
sympathetic dominance, in women with PCOS (Hashim et al., 2015; Ribiero et al., 
2016). As such, we measured HRV in all subjects during pace breathing in MSNA 
studies, and with paced breathing in subjects in whom we were unable to obtain adequate 
nerve recordings. Subjects were resting in the supine position in a dark, thermoneutral 
room (18-21°C) for a minimum of 20 minutes prior to testing. Heart rhythm 
was measured using a 3-lead EKG (CardioCap; Datex Ohmeda, Louisville, CO) while 
breathing to a metronome paced at 15 breaths/min for five minutes.  Data were 
continuously recorded at 250Hz (Windaq, Dataq Instruments, Akron, OH) for offline 
analysis including peak detection of R waves and examination of heart rate variability 
using commercially available software (HRVanalysis 1.1) (Pichot et al., 2016). Variables 
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of interest within time domain analyses of total variability included the standard deviation 
of normal-to-normal R-R intervals (SDNN) and the square root of the mean sum of 
squared differences (rMSSD).  Frequential analyses were additionally employed 
to measure total variability (Ptot) and to estimate the relative contribution of 
parasympathetic and sympathetic modulation using low frequency (LF, LFnu; defined as 
0.04-0.15Hz), high frequency (HF, HFnu; defined as 0.15-0.4Hz), and the ratio of low to 
high frequency (LF/HF). 
Blood analysis. On a separate day, blood samples were drawn from a venous 
catheter in the antecubital space for analysis of insulin, testosterone, adipokines, and 
various inflammatory cytokines. Blood was collected in serum separator tubes and 
allowed to clot for 30 minutes at room temperature prior to centrifugation. Samples were 
then centrifuged at 1500 x g for 10 minutes at 4°C, then placed in a -80°C freezer. 
Thawed samples were batch-analyzed at the end of the study for total testosterone using a 
commercial ELISA kit (Enzo life sciences), while inflammatory markers IL-6, IL-1β, 
TNFα were examined in EDTA-treated plasma with a commercial cytometric bead-based 
array (BD Biosciences Human Inflammatory Panel) using flow cytometry (Beckman-
Coulter Gallios). Serum insulin was analyzed by Oregon Clinical and Translational 
Research Institute (OCTRI). 
Statistics. All results are reported as mean ± SEM. Results were compared using a 
two-way mixed model ANOVA with Graphpad Prism 6, and significant main effects 
were examined using Holm-Sidak post-hoc analysis. Based on results from an exercise 
intervention in PCOS women, a power analysis for our primary variable of interest 
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(MSNA burst frequency) using conventional α=0.05 and β=0.80 determined a minimum 
sample size of six subjects/group. 
Results 
Of the eighteen women 
who participated in the study, 
successful nerve recordings were 
obtained on 14 individuals (7 HT, 
7 CON), with one HT subject 
missing mid-point MSNA. 
Demographic data are presented 
in Table 5. All subjects were 
classified as obese and diagnosed 
with PCOS using the Rotterdam 
criteria. Using the most recent 
guidelines for hypertension, seven 
subjects (3 HT, 4 CON) were 
classified as “elevated blood 
pressure”, and seven were 
classified as Stage 1 Hypertensive 
(4 HT, 3 CON). Two subjects in 
each group were classified as 
normotensive (<120/<80 mmHg). HT 
Figure 18. Change in blood pressure over 
time in HT and CON. * Denotes significant 
difference from Pre (time within group) and 
CON (between group at matched timepoint) 
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subjects experienced a large, clinically significant decrease in blood pressure (10mmHg 
decrease in MAP; see Figure 18) with no change over time in CON subjects (Figure 18). 
By the end of testing, only one HT subject had not changed classification (elevated blood 
pressure), despite experiencing a 3mmHg decrease in MAP. HT subjects also 
experienced a significant decrease in resting heart rate over time (Pre: 73 ± 4; Mid: 68 ± 
3; Post: 64 ± 3 beats/min, p=0.003 Pre vs Post), while HR in CON subjects did not 
change (Pre: 74 ± 5; Mid: 74 ± 4; Post: 72 ± 4 beats/min, p=0.53 Pre vs Post). 
MSNA.  
MSNA 
significantly 
declined over the 
course of HT, with 
an approximately 
~40% decline in 
burst frequency 
evident at the mid-
point, and no 
change in CON 
subjects. Individual data 
for all subjects for both burst frequency and incidence are shown in Figure 19. All HT 
subjects exhibited a decrease in baseline MSNA by the mid time point, which was 
maintained in post testing, and no changes over time were observed in CON subjects.  
Figure 19. Individual MSNA burst frequency (BF) and 
incidence (BI) in HT and CON. HT subjects experienced a 
significant decrease in BF and BI in Mid and Post 
compared with Pre. 
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Baroreflex Sensitivity. Baroreflex sensitivity was assessed during the Valsalva 
maneuver by comparing baseline burst incidence (BI) and diastolic blood pressure (DBP) 
to BI during the five lowest consecutive DBPs during Phase II in order to calculate slope 
(∆BI/∆DBP). Due to the significant decrease in DBP, HT subjects exhibited a shift in 
intercept to a lower set point at Mid and Post, with no change in CON (Figure 20). BI 
Figure 20. sBRS slopes in HT (a) and 
CON (b). HT subjects experienced a 
decrease in set point and increase in 
sensitivity (more negative slope) 
compared to CON (c). *Denotes 
significant difference from CON in Post. 
 
 
 
a 
b 
c 
 89 
 
slope (∆BI/∆DBP) significantly decreased, indicating increased sBRS sensitivity, in HT 
subjects as compared to CON (interaction effect p=0.003; Figure 20c). 
Heart Rate Variability. Measures of total variability (rMSSD, SDNN, Ptot) are 
displayed in Table 6. While measures of total variability tended to increase throughout 
testing in HT subjects and remain stable in CON, only rMSSD significantly increased 
over time in HT subjects (p=0.043). In the frequency domain, both LF and HF tended to 
increase over time, resulting in no change in LFnu, HFnu, or LF/HF in either group. 
  Pre Mid Post 
SDNN HT 
CON 
47 ± 6 
53 ± 7 
53 ± 9 
55 ± 8 
62 ± 7 
57 ± 8 
rMSSD HT 
CON 
44 ± 6 
53 ± 9 
45 ± 11 
 48 ± 12 
66  ± 9 
54 ± 13 
Ptot HT 
CON 
2365 ± 704 
2275 ± 615 
2666  ± 704 
2906 ± 803 
3757  ± 1317* 
3213 ± 873 
LFnu HT 
CON 
37 ± 9 
30 ± 6 
54  ± 6 
43 ± 10 
37  ± 6 
35 ± 6 
HFnu HT 
CON 
50  ± 8 
64 ± 6 
40  ± 6 
50 ± 10 
54  ± 8 
48 ± 11 
LF/HF HT 
CON 
1.16  ± 0.44 
0.55 ± 0.16 
1.61  ± 0.31 
1.69 ± 0.76 
1.01 ± 0.35 
1.11 ± 0.44 
 
 
Table 6. Heart rate variability over time in HT and CON. *denotes significant difference 
from Pre within group. 
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Blood parameters. Most subjects had elevated total testosterone at Pre (>30 
ng/mL), excluding the one subject in each group taking oral contraceptives (Table 7). Of 
the remaining six subjects who underwent HT and were not taking oral contraceptives, 
five reported beginning regular menstrual cycles by the mid-point of the study. In these 
five women, serum testosterone decreased from 65 ± 9 to 38 ± 7 ng/mL (mean change 27 
± 9 ng/mL) over HT. Total testosterone significantly decreased over time in HT subjects 
(p=0.03), with no change in CON (p=0.21). Serum Insulin was elevated and did not 
change in either HT or CON. For cytokine analysis, one HT and one CON subject fell 
below the detectable limits for all analytes, so data represent n=8 experimental and n=7 
control.  IL-6, IL-1β, and TNF were variable in control subjects, but tended to decrease 
over time in HT. IL-1β significantly decreased over time in HT as compared with CON 
(interaction effect p=0.0404), and TNF tended to decrease over time in HT compared 
with CON (interaction effect p=0.0689). While IL-6 decreased in all HT subjects, this 
change was not statistically significant (p=0.17).  
Correlation Analysis. As seen in Figure 21, change in total testosterone 
(Calculated as Mid – Pre and Post – Pre in HT and CON) was significantly correlated 
with change in MSNA BF (r=0.64), BI (r=0.65), and baroreflex slope (r=0.54). Change in 
insulin over time was not significantly correlated with change in MSNA BF (r=0.22), BI 
(r=0.14), or baroreflex slope (r=0.07). Similarly, change in IL-6 and TNFα were not 
significantly correlated with change in MNSA BF (r=0.25 and 0.11, respectively), BI 
(r=0.29 and 0.04, respectively), or baroreflex slope (r=0.03 and 0.27, respectively). 
 91 
 
 
Discussion 
 
This study was the first to examine changes in MSNA and HRV at rest in 
response to a chronic heat intervention. The large reduction in baseline MSNA, clinically 
important reduction in resting blood pressure, increased sBRS sensitivity, and 
improvement in inflammatory profile work in concert to reduce cardiometabolic risk and 
provide evidence of significant clinical benefits of heat therapy to women with PCOS. 
The elevated MSNA in obese women with PCOS not only contributes to cardiometabolic 
dysfunction, but also contributes to ovarian dysfunction, therefore the observed reduction 
in MSNA may be related to reductions in serum testosterone and improvements in PCOS 
symptoms observed in this investigation. 
  Pre Mid Post 
Total Testosterone 
(ng/mL) 
HT 
CON 
51 ± 8 
42 ± 4 
42 ± 3 
39 ± 8 
34 ± 4* 
46 ± 7 
Serum Insulin 
(mU/L) 
HT 
CON 
23 ± 4 
26 ± 2 
22 ± 5 
25 ± 2 
23 ± 4 
22 ± 2 
IL-1β 
(pg/mL) 
HT 
CON 
23 ± 7 
15 ± 4 
12 ± 5 
28 ± 10 
12 ± 6# 
28 ± 9 
IL-6 
(pg/mL) 
HT 
CON 
19 ± 10 
14 ± 3 
10 ± 8 
20 ± 7 
1 ± 1 
16 ± 5 
TNFα 
(pg/mL) 
HT 
CON 
24 ± 7 
13 ± 3 
13 ± 6 
17 ± 2 
9 ± 6 
12 ± 3 
Table 7. Blood parameters over time in HT and CON. *denotes significant 
difference from Pre within group. #denotes significant difference from CON. 
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 The ~40% reduction in 
burst frequency and incidence 
after 4-5 weeks of heat therapy 
in this study is similar in 
magnitude to changes observed 
in response to 16 weeks of 
exercise training or 
electroacupuncture in 
overweight women with PCOS 
(Stener-Victorin et al., 2009). 
This decrease persisted through 
post HT testing, and was 
accompanied by clinically 
significant decreases in SBP, 
DBP, MAP, and heart rate. 
Together, this shift in baseline 
MSNA firing rate and lower 
blood pressure indicate a change 
in baroreflex set point with heat 
therapy. This change was also 
evident when examining sBRS slope, 
with HT subjects exhibiting a shift to 
Figure 21. Correlation analysis of change in 
total testosterone and MSNA variables. 
Change in BF, BI, and sBRS were all 
significantly correlated with change in 
testosterone. 
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a lower firing rate and pressure in Mid and Post, and a steeper slope in Post. Since greater 
baroreflex sensitivity is associated with healthier cardiovascular profiles (Eckberg & 
Sleight, 1992), this change in slope further contributes to the improved cardiovascular 
risk profile with heat therapy. 
 In obese women with PCOS, there are multiple factors associated with elevated 
MSNA, including obesity (Narkiewicz et al., 1998), hyperinsulinemia (Monroe et al., 
2000),  inflammatory cytokines (Zhang et al., 2003; Helwig et al., 2008), and androgen 
excess (Sverrisdottir et al., 2008). BMI and fasting insulin did not change over the course 
of the study and are therefore unlikely responsible for changes in MSNA. However, HT 
subjects experienced a decrease in circulating  TNFα. TNFα tends to be elevated in obese 
women with PCOS (Escobar-Morreale et al., 2011; Shorakae et al., 2015; Spritzer et al., 
2015) and increases sympathetic outflow at the rostral ventrolateral medulla (Marz et al., 
1996; Zhang et al., 2003). While changes in circulating inflammatory cytokines may 
modulate sympathetic activity, the changes in IL-6 and TNFα in this study did not 
significantly correlate with changes in MSNA variables. Finally, women in the HT 
intervention experienced a decrease in testosterone over time. Elevated serum 
testosterone has been associated with sympathetic activity in PCOS, although there is 
some debate whether testosterone drives sympathetic activity (Sverrisdottir et al., 2008) 
or if high sympathetic activity to the ovary drives androgen production (Lara et al., 
1993). We observed a moderate correlation between in changes in MSNA and changes in 
testosterone in the women in this study. However, it remains unclear whether this is a 
correlative or causative relationship, as we did not independently manipulate either 
variable in isolation. 
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 Alterations in baroreflex sensitivity were also correlated with changes in total 
testosterone. While estrogen and progesterone have been shown to alter sympathetic 
and/or cardiovagal baroreflex sensitivity in women (Mohamed et al., 1999; Minson et al., 
2000a, 2000b; Brunt et al., 2013) and testosterone appears to increase baroreflex 
sensitivity in older men with heart failure (Caminiti et al., 2009), no studies have 
assessed the impact of testosterone on baroreflex sensitivity in women. However, it is 
possible that changes in sBRS are unrelated to changes in testosterone and are driven by 
other unknown mechanisms with heat therapy. For example, baroreflex sensitivity is 
positively associated with endothelial nitric oxide synthase (eNOS) and NO 
bioavailability (Paton et al., 2001), and heat acclimation or heat therapy is associated 
with enhanced NO production (Pritchard et al., 2001; Harris et al., 2008; Bharati et al., 
2017) . In addition, Angiotensin II receptor subtype 2 (AT2) increase baroreflex 
sensitivity via NO-dependent mechanisms, and AT2 receptor density increased in the rat 
hypothalamus with heat acclimation (Horowitz et al., 1999). If a similar change in NO 
bioavailability and AT2 receptor density occurred in the women in this study, these 
mechanisms could be responsible for the observed changes in baroreflex sensitivity. As 
NO and AT2 receptors both act centrally to reduce baseline sympathetic outflow (Wong 
et al., 1992; Schwarz et al., 1995; Abdulla & Johns, 2017), these mechanisms could 
additionally explain the reduction in baseline MSNA. 
 The change in MSNA, total testosterone, and reported changes in menstrual 
regularity deserve further comment. While attributing causation to any one variable is 
difficult, the theory that high sympathetic activity to the ovary drives ovarian dysfunction 
(Lara et al., 1993) and androgen production matches the time course of observed 
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decreases in MSNA (evident by Mid testing) and total testosterone (not significantly 
decreased until Post). However, insulin resistance, inflammation, and many other 
variables may contribute to ovarian dysfunction and elevated MSNA, so it is possible that 
changes in inflammation, insulin sensitivity (Chapter V), or myriad unknown factors 
decreased MSNA and improved ovarian function. 
As an attempt to examine autonomic function in subjects we were unable to obtain 
nerve tracings, we measured heart rate variability (HWV) during supine rest. While 
measures of total variability tended to increase, individual responses did not match the 
timecourse or magnitude of changes in MSNA during HT. Further, we did not observe a 
shift in LF/HF despite clear changes in MSNA with HT. Use of the LF/HF ratio to asses 
sympathetic and parasympathetic influence of heart rate involves a series of assumptions, 
and, while widely used, some researchers convincingly argue it does not accurately 
reflect sympathovagal balance (Billman, 2013). While muscle sympathetic nerve activity 
is distinct from cardiac sympathetic nerve activity, the significant decrease in systolic 
blood pressure and heart rate indicated an effect of heat therapy on sympathovagal 
control of cardiac function that was not evident in measures of HRV. 
In summary, heat therapy resulted in profound decreases in blood pressure and 
MSNA in obese women with PCOS, a population with well-described sympathetic 
overactivity and elevated risk of hypertension. These changes not only resulted in a 
reduction in hypertensive risk category for HT subjects, they were accompanied by 
changes in serum testosterone and self-reported menstrual function. Heat therapy holds 
great promise as a lifestyle intervention in obese women with PCOS to reduce MSNA 
and improve ovarian function, although mechanisms behind these improvements are 
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unclear. The inter-relationships between testosterone, inflammation, other neurohumoral 
or hormonal changes and changes in MSNA in obese women with PCOS require further 
investigation. 
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CHAPTER VI 
 
HEAT THERAPY AND METABOLIC FUNCTION IN OBESE WOMEN WITH PCOS 
 
Polycystic ovary syndrome (PCOS) is a complex neuroendocrine disorder that 
affects 5-18% of women  (Spritzer et al., 2015; Dunaif, 2017) and is characterized by 
clinical hyperandrogenism, menstrual dysfunction, and presence of ovarian cysts 
(Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, 2004). In 
addition to well-described reproductive health issues, the metabolic and hormonal 
profiles in women with PCOS greatly increase the risk for obesity, insulin resistance, and 
diabetes (Luque-Ramírez & Escobar-Morreale, 2014).  The PCOS phenotype displays 
insulin resistance through a spectrum of BMI from lean to obese (Stovall et al., 2011), 
but with over 50% of women with PCOS classified as obese (Gambineri et al., 2002), 
obese women with PCOS exhibits marked insulin resistance and an elevated risk of 
developing Type II diabetes.   
Insulin signaling is disrupted in adipose tissue (Ciaraldi et al., 1997; Echiburú et 
al., 2018) in obese PCOS women, resulting in impaired glucose uptake and incomplete 
suppression of free fatty acid release (Zierath et al., 1998). These circulating fatty acids 
can accumulate in the liver and skeletal muscle and produce fatty acid intermediates such 
as diacylglycerol, ceramides, and long-chain fatty acid-Acyl CoA (Koves et al., 2008), all 
of which can inhibit intracellular insulin signaling by activation of c-Jun NH2-terminal 
Kinase (JNK) (Nguyen et al., 2005) or Inhibitor of kappa B kinase β (IKKβ) (Yuan et al., 
2001; Arkan et al., 2005). JNK and IKKβ impair intracellular insulin signaling by serine 
phosphorylation of the insulin receptor substrate, preventing downstream signaling (Yin 
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et al., 1998). This results in systemic insulin resistance with an impaired ability of cells to 
transport glucose or suppress glucose production, creating a hyperglycemic, 
hyperinsulinemic profile in PCOS (Burghen et al., 1980). This insulin resistance is 
exacerbated by factors such as low serum adiponectin, elevated systemic inflammation, 
and disruptions in the PI3K-Akt signaling pathway in PCOS (Li et al., 2017). While 
medications such as Metformin (Tang et al., 2006) and lifestyle interventions such as diet 
and exercise (Giallauria et al., 2008; Covington et al., 2016) can improve this metabolic 
dysfunction, most research suggests that they are unable to fully restore insulin 
sensitivity, therefore warranting investigation of alternative or adjunctive therapies 
Repeated heat exposure, through hot water immersion, has been investigated in 
human and animal models of diabetes and insulin resistance. Promising reductions in 
fasting blood glucose were seen in Type 2 diabetics after two weeks of hot tub use 
(Hooper, 1992), although no measures of insulin were taken. In animals exposed to 
repeated heat shock, improvements in glucose tolerance and skeletal muscle glucose 
uptake were observed (Gupte et al., 2009). Similar results were seen in select white 
adipose tissue depots, with improved insulin signaling following a single bout of heat 
treatment (Rogers et al., 2015). These improvements were associated with increased heat 
shock protein abundance in muscle and adipose tissue, which acted to inhibit 
accumulation and activation of inflammatory proteins such as JNK and IKKβ. 
Specifically, Hsp27 is associated with inhibition of the inflammatory compound IKKβ 
(Park et al., 2003), while Hsp70 inhibits the activation of JNK (Park et al., 2001) and 
additionally acts to repair damaged insulin receptors (Zachayus et al., 1996) through its 
well-described roles in molecular chaperoning and protein refolding (Kregel, 2002). 
 99 
 
Hsp90 does not appear to play a role in insulin signaling, but is involved in adipocyte 
differentiation and fat mass accumulation (Desarzens et al., 2014).  In support of the 
relationship between HSP abundance and metabolic health in humans, low levels of 
HSPs in adipose tissue have been observed in patients with Type II diabetes (Hooper & 
Hooper, 2009). In concert, these studies show great potential for heat therapy to improve 
insulin signaling and glucose tolerance in insulin-resistant humans, but no study has yet 
investigated the effect of heat therapy on markers of metabolic health and adipose tissue 
specific insulin signaling and inflammation. 
Therefore, the purpose of this study was to observe the impact of heat therapy on 
metabolic health in obese women with PCOS. Assessment of metabolic health included 
body mass index, circumference and skinfold thickness measures, glucose and insulin 
responses to an OGTT, and changes in inflammation, HSP expression, and insulin 
signaling in subcutaneous adipose tissue in order to examine potential mechanisms 
behind changes in glucose tolerance. We hypothesized that heat therapy would improve 
glucose tolerance and enhance insulin signaling in adipocytes, and that these changes 
would occur in the absence of changes in BMI or body composition. Based on previous 
work in animals exposed to heat treatment (Gupte et al., 2009; Rogers et al., 2015), we 
additionally hypothesized that HSP abundance would increase and inflammatory markers 
would decrease in subcutaneous adipose tissue.  
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Methods 
 
Subjects. Eighteen obese (body mass index; BMI 30-45) women with PCOS 
participated in this study (Age: 27 ± 2 years; BMI: 40.9 ± 1.1 kg/m2), with nine subjects 
assigned to a heat therapy intervention (HT) and nine assigned to a time control group 
(CON). Subjects were matched for BMI and age between groups. All subjects were non-
smokers, not diagnosed with overt cardiovascular disease or diabetes, and were not taking 
medications known to impact insulin sensitivity (Metformin, Spironolactone), with the 
exception of one subject in each group taking oral contraceptives. Of these eighteen 
subjects, adipose tissue biopsies were performed on sixteen of them (8 experimental, 8 
control).  
Heat Therapy Intervention. Heat therapy occurred over an eight to ten week 
period, with a total of 30 x one hour sessions scheduled three to four per week in all 
subjects enrolled in the experimental group (control subjects were not exposed to heat). 
Passive hot water immersion was selected as the method of heat stress because it is 
capable of increasing core temperature at a rate similar to moderate-intensity exercise 
(Kenny et al., 1996), while also allowing high skin temperature and sweating rate, all 
requisite components for adaptation to heat (Fox et al., 1963; Buono et al., 2009). 
Subjects reported to the laboratory to undergo passive heating, which entailed 60 
min of water immersion in a bath set to 40.5°C. Previous research in our laboratory 
suggests this temperature is optimal to raise core temperature ≥ 38.5°C within 20-30 
minutes. Once core temperature rose to 38.5°C, subjects sat upright (immersed to the 
waist) for the remainder of the one hour session in order to maintain core temperature 
between 38.5-39.0°C. If temperature dropped below 38.5, subjects were asked to 
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submerge again. After 60 minutes of exposure, subjects were asked to sit next to the tub 
until core temperature fell below 38.5˚C (10-15 minutes) for safety monitoring, and for 
monitoring the total exposure duration where core temperature was above 38.5°C. This 
threshold was selected based on human heat acclimation literature using isothermic 
models (Fox et al., 1963), and is additionally important as a threshold for induction of 
heat shock proteins (Taylor, 2014). 
On each heat therapy day, subjects provided a urine sample for measurement of 
specific gravity (USG) to confirm euhydration (USG ≤ 1.02) prior to heat exposure. 
Subjects were also weighed pre- and post-heat exposure (nude, towel-dried, behind a 
privacy screen) and given water to drink ad libitum during heat exposure and post-heat 
exposure if necessary to match fluid losses. Heart rate was monitored throughout heating 
using commercially-available heart rate monitors (Polar Electro, New York, NY), while 
rectal temperature (Tre) was monitored throughout passive heating by rectal thermistor 
(YSI, Yellow Springs, OH).  
 
Oral Glucose Tolerance Test (OGTT).  Selection of a 2-hr, 75g OGTT was based 
on its wide clinical utility, well-established thresholds for impaired fasting glucose and 
impaired glucose tolerance, and its inclusion as part of recommended screening for all 
obese women diagnosed with PCOS (Azziz et al., 2006). An OGTT was performed in all 
subjects at the beginning (Pre, 0 HT sessions or time control), mid-point (Mid, 14-16 HT 
sessions or equivalent 4-5wk time control), and end (Post, 36-72h after 30th heat session 
or equivalent 8-10 week time control). Subjects arrived at the laboratory following an 
overnight fast (≥12hr) and having refrained from caffeine and alcohol for 12 hours, 
vitamin supplements and medications for 24 hours, and heavy exercise or heat exposure 
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for >24 hours. In addition, diet was recorded using a 24-hour food recall to ensure similar 
macronutrient composition between tests for each subject.  
Upon arrival, body mass index (BMI=Weight in kg/[Height in m]2), waist and hip 
circumference, and 3-site skinfold thickness (tricep, suprailiac, thigh) were assessed 
using established techniques. Following anthropometric assessment, subjects were seated 
in a comfortable chair for a minimum of 15 minutes prior to catheter placement. A 
venous catheter was inserted into a vein in the antecubital space or hand and baseline 
samples were drawn into syringes, then placed into appropriate tubes. Samples were 
placed in EDTA tubes for analysis of glucose (YSI 2300 Stat Plus, Yellow Springs, OH) 
and serum separator tubes (SST) for analysis of insulin. The EDTA tubes were 
immediately placed on ice and centrifuged, while the SSTs were allowed to clot at room 
temperature for 30 minutes prior to centrifugation. In addition, fasting samples were also 
drawn for measurement of various cytokines and adipokines associated with impaired 
metabolic health. All samples were centrifuged at 1500 x g for 10 minutes at 4°C, and 
plasma or serum was aliquoted into cryovials and placed in -80°C freezer. 
After baseline (fasted) sampling, a 75-g glucose drink was ingested in a 3-5 
minute period, and blood samples were taken at 15, 30, 45, 60, 90, and 120 minutes for 
analysis of blood glucose and insulin. Glucose was analyzed using the glucose oxidase 
method (YSI 2300 Stat Plus, Yellow Springs, OH), and insulin samples were frozen at -
80°C for batch analysis by Oregon Clinical and Translational Research Institute 
(OCTRI). 
The resulting glucose and insulin curves provide an indication of glucose 
tolerance and insulin sensitivity through measurement of the area under the curve for 
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both glucose and insulin. In addition, commonly used fasting markers of insulin 
resistance were calculated as assessments of insulin resistance (Piché et al., 2007). These 
included the homeostatic model assessment for insulin resistance (HOMA-IR=[glucose 
mg/dL*insulin mU/L]/405) and quantitative insulin sensitivity check index 
(QUICKI=1/[Log(glucose) +Log(insulin)]), both calculated on values obtained after a 
12-hr overnight fast. 
Adipose Tissue Biopsies. Subcutaneous white adipose tissue samples were 
obtained after a 4-hour fast from the peri-umbilical area at the beginning (Pre, 0 HT 
sessions or time control) and end (Post, 36-72h after 30th heat session or equivalent 8-10 
week time control) of the study in HT and CON subjects. This tissue depot was selected 
due to the high proportion of abdominal obesity in PCOS, and the ease of sampling & 
relative comfort of participants. The sampling area was cleaned with antiseptic 
(Chloraprep) and a local anesthesia was induced by intracutaenous and subcutaneous 
injection of 5ml of 1% lidocaine near the site of incision in the side of the umbilicus. 
Following local anesthesia, a 3mm wide skin incision was made with a sterile scalpel at 
the edge of the umbilicus, and 15 cm lontrog, 16 gauge infiltration cannula (Millenium 
Surgical, Narbeth, PA) was advanced through the incision. This cannula was connected 
to a 60-ml syringe containing a mixture of 50 ml of 0.9% sterile saline and 7.5mL of 1% 
lidocaine. This fluid was injected in the sub-cutaneous fat in a fan-like fashion from the 
incision site, covering a total area of ~5x5cm. Next, an 11 gauge aspiration cannula 
(Millenium Surgical, Narbeth, PA) connected to a 20mL sterile syringe was advanced in 
the same fan-like fashion while gentle suction was applied. A total sample of 10-12mL of 
fluid and fat was taken, resulting in an adipose tissue sample of 4-7mL. This sample was 
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collected and washed three times in sterile saline before a portion of whole adipose tissue 
was snap-frozen in liquid nitrogen for later analysis of HSPs and inflammatory markers. 
The remaining sample was placed in phosphate-buffered saline (PBS) for adipocyte 
isolation.  
Primary adipocytes were isolated by digesting tissue with collagenase (1mg/mL in 
KRH buffer) at 37°C. When tissue chunks were no longer visible, the sample was passed 
through a 250um Pierce tissue strainer (Thermofisher Scientific, Rockford, IL) and 
washed with an equal volume of wash buffer (KRH buffer with 10uL adenosine and 2% 
BSA) before centrifugation at 500 x g for 5 minutes. The wash buffer and centrifugation 
process was repeated, then 3 x 100uL cell samples were each placed in wash buffer for a 
two hour serum-starve incubation at 37°C. 
After incubation, one sample was left untreated and 20 µL insulin (Humulin-R; 
Lilly Pharmaceuticals) was added to the second and third samples in physiological 
(1.2ng/mL) and supra-physiological (12ng/mL) concentrations. These samples were 
placed in a 37°C incubator for five minutes before adipocytes were extracted and snap-
frozen in liquid nitrogen for later analysis of insulin signaling by measuring 
phosphorylated AKT (p-AKT). Isolated adipocytes were thawed and combined with a 1:1 
volume of protease inhibitor cocktail for tissue homogenization. Homogenized samples 
were rotated at 4°C for one hour, then spun at 1200 x g for 15 minutes prior to protein 
subnatant extraction and quantification. Analysis of p-AKT was completed using Wes 
(ProteinSimple, San Jose, CA) as previously described (Harris, 2015). 
Whole adipose tissue samples were thawed and combined with a cocktail of 10X 
RIPA (AbCam, Cambridge, MA) and protease inhibitors in a 1:1 sample:cocktail mixture 
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before homogenization. Homogenized samples were spun at 1500 x g for 10 minutes, and 
protein extract was isolated from beneath the lipid layer of each sample. Samples were 
analyzed for Hsp27 (Santa Cruz Biotecnology, Santa Cruz, CA), Hsp70 (AbCam, 
Cambridge, MA), Hsp90 (AbCam, Cambridge, MA) and inflammatory markers JNK, p-
JNK, and IKKβ (Santa Cruz Biotechnology, Santa Cruz, CA) using Western Blotting, 
with α-Vinculin (AbCam, Cambridge, MA) used as a loading control. 
Statistics. All data are presented as mean ± SEM. Results were analyzed using mixed-
model ANOVA in GraphPad Prism 6, with repeated measures within HT or CON groups 
for each subject over time, and non-repeated measures comparison between groups of 
subjects. If a significant main effect was observed, Holm-Sidak post-hoc analysis was 
utilized to examine within- or between-group effects over time. 
 
Results 
All HT subjects completed the heat therapy intervention, and exhibited classic 
signs of heat adaptation including a reduced basal body temperature, lower heart rate, and 
increased sweating rate upon exposure to heat (Chapter IV Table 3). One CON subject 
withdrew after all Pre testing was complete, and was therefore not included in analyses. 
CON and HT subjects did not exhibit any changes in BMI, waist circumfrence, waist to 
hip ratio, or skinfold thickness over the course of 8-10 weeks (Table 8). Despite this, 
HOMA-IR decreased and QUICKI increased from Pre to Post, both indicating increased 
insulin sensitivity. 
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Table 8. A summary of anthropometric and blood variables related to metabolic health in 
heat therapy (HT) and control (CON) subjects. * indicates significantly (p<0.05) different 
from Pre.  
 Group Pre Mid Post 
BMI  
(kg/m2) 
HT 
CON 
41.8 ± 1.4 
39.9 ± 1.9 
41.9 ± 1.4 
39.8 ± 1.8 
41.8 ± 1.5 
39.5 ± 1.8 
Waist circumfrence  
(cm) 
HT 
CON 
111 ± 2 
109 ± 4 
111 ± 2 
109 ± 4 
110 ± 3 
109 ± 4 
Waist:Hip ratio HT 
CON 
0.85 ± 0.01 
0.86 ± 0.02 
0.85 ± 0.01 
0.86 ± 0.02 
0.84 ± 0.01 
0.85 ± 0.02 
Sum of skinfolds  
(mm) 
HT 
CON 
137  ± 6 
132 ± 8 
138 ± 8 
134 ± 7 
135 ± 7 
138 ± 8 
HOMA-IR HT 
CON 
5.9 ± 0.9 
6.4 ± 0.5 
5.5 ± 1.2 
6.3 ± 0.5 
4.9 ± 0.9* 
6.2 ± 0.5 
QUICKI HT 
CON 
0.30 ± 0.01 
0.29 ± 0.01 
0.31 ± 0.01 
0.29 ± 0.01 
0.31 ± 0.01* 
0.29 ± 0.01 
     
 
OGTT. All subjects exhibited abnormalities in the OGTT at baseline including 
impaired fasting glucose (n=2 HT, 4 CON; with n=1 HT and 1 CON in pre-diabetic 
range), elevated 2-hr glucose (n=3 HT, 1 CON), or both (n=4 HT, 4 CON). No glucose 
parameters significantly changed in CON or HT subjects at the mid-point of the study; 
however; at the end of the intervention HT subjects displayed reduced fasting glucose, 
and lower blood glucose values beginning at 45 minutes (Figure 22). These reductions in 
glucose resulted in a decreased glucose area under the curve (AUC, Figure 22 insets) in 
HT subjects at Post-testing. Fasting insulin did not change over HT, but insulin during the 
OGTT was significantly reduced at the 45, 60, 90, and 120min timepoints in Post, 
resulting in a decreased insulin AUC in HT subjects. Inulin AUC was also significantly 
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reduced at the Mid-point in HT subjects. All glucose and insulin data for HT and CON 
subjects are displayed in Figure 22. 
Insulin Signaling. Subjects in HT and CON displayed a stepwise increase in p-
AKT with increasing insulin dose in Pre samples (Figure 23). In Post samples, this 
stepwise increase was still evident in CON, but in HT subjects, sub-max and max doses 
were not different, indicating that the sub-max dose was adequate to maximize response 
after HT. Individual data for the sub-max dose are displayed in Figure 24. This change in 
p-AKT in response to insulin following HT represented a ~500% increase Pre to Post. 
 
Figure 22. Glucose and insulin curves at Pre, Mid, and Post for HT (left 
panels) and CON (right panels). Glucose and insulin AUC are displayed as 
insets in each graph. * denotes significantly different from Pre 
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In order to examine potential cellular signals that may be driving this increase in 
insulin signaling, common inflammatory markers IKKβ, JNK and p-JNK were examined 
in whole adipose tissue. As seen in Figure 25, a ~40% decrease in IKKβ (p=0.024) was 
observed following HT, with no change in CON subjects (p=0.49). While most HT 
subjects tended to decrease from Pre to Post, changes in JNK (~28% decrease; p=0.09 
and  p-JNK (~27% decrease; p=0.11) were not statistically significant following HT, and 
the ratio of pJNK/JNK (p=0.70) did not change. No changes were observed in CON 
subjects for JNK (p=0.32),  p-JNK (0.42), or p-JNK/JNK (p=0.29). 
 
Figure 23. Insulin signaling (p-AKT) relative to loading control (GAPDH) at basal (no 
insulin), sub-max (1.2nM), and max (12nM) insulin doses in HT and CON. *Denotes 
significantly different from Pre. 
Figure 24. Individual responses of insulin 
signaling (p-AKT) relative to loading 
control (GAPDH) to 1.2nM insulin dose in 
HT (dark circles) and CON (open circles). 
*denotes significantly (p<0.05) different 
from Pre. 
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Hsp27 abundance 
increased in HT subjects 
(p=0.008), with a mean 
increase of ~70% and no 
change in CON (p=0.72). 
However, no changes in 
Hsp70 (p=0.79) or Hsp90 
abundance (p=0.50) were 
observed following HT. 
 
Discussion 
This study examined 
the impact of a 30-session, 8-
10 week heat therapy 
intervention on markers of 
metabolic health in obese 
women with PCOS. Our 
primary findings indicate that 
repeated heat exposure is a 
potent stimulus to improve 
glucose tolerance, reduce 
markers of inflammation, and improve insulin sensitivity in a population with marked 
insulin resistance. Importantly, these improvements occurred in the absence of any 
Figure 25. Individual IKKβ, JNK, and p-JNK 
abundance in HT and CON subjects, expressed 
relative to loading control (Vinculin). *Denotes 
significant difference from Pre. 
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changes in BMI or body 
composition in our subjects. 
This lack of change in 
anthropometric measures 
suggests that heat therapy-
mediated improvements in 
metabolic function are body 
mass-independent, and could 
therefore complement lifestyle 
modifications that lead to 
weight loss in obese women 
with PCOS. 
The improvements in 
blood glucose during an 
OGTT in HT subjects are on 
par with those observed in hot 
yoga interventions in obese 
men and women (Hunter et 
al., 2013a), and greater than 
those observed in exercise 
training interventions in PCOS 
(Costa et al., 2018). Additionally, 
the decrease in fasting and 2-hr 
Figure 26. Individual Hsp27, 70 and 90 
abundance in HT and CON subjects, expressed 
relative to loading control (Vinculin). *Denotes 
significant difference from Pre. 
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glucose observed in HT individuals changed the risk category for six of nine HT subjects 
(from pre-diabetic to impaired, or from impaired to optimal classification). While we 
realize an OGTT is not specifically a measure of insulin sensitivity, results correlate well 
with gold standard measures of insulin sensitivity (Euglycemic-Hyperinsulinemic clamp 
technique) (DeFronzo et al., 1979), with the strongest correlations in individuals with 
some degree of insulin resistance (Stumvoll et al., 2000; Piché et al., 2007). Additionally, 
we observed a significant decrease in HOMA-IR and insulin AUC, and a significant 
increase in QUICKI, which in concert indicate increased whole-body insulin sensitivity. 
HOMA-IR and QUICKI values for the women in this study met established thresholds 
for insulin resistance (>2.0 and ≤0.30, respectively), and the changes in these values were 
clinically meaningful but not large enough to alter risk classification. 
The systemic improvement in markers of insulin sensitivity and insulin-stimulated 
glucose uptake during the OGTT were supported by changes in insulin signaling in 
subcutaneous fat samples. While visceral fat appears to have a stronger relationship with 
metabolic dysfunction (Wajchenberg et al., 2002) and insulin resistance (Preis et al., 
2010) in obesity, obese women with PCOS exhibit dysfunction in both visceral and 
subcutaneous depots in the abdominal region (Echiburú et al., 2018). The improvement 
in insulin signaling observed in subcutaneous white adipose tissue along with a reduction 
in IKKβ and increase in Hsp27 creates a possible mechanism for heat-mediated 
improvements in whole-body glucose disposal. It appears that heat stress, potentially 
through changes in Hsp27 abundance, reduced adipose tissue inflammation such that 
insulin signaling was improved within fat. Based on the increased glucose uptake despite 
a decreased insulin response during the OGTT, heat therapy also likely improved insulin 
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sensitivity in the liver and skeletal muscle. While we did not examine HSPs, 
inflammatory proteins, or insulin signaling in skeletal muscle, muscle is the largest 
glucose sink and primarily responsible for glucose uptake in an OGTT. Therefore, the 
reduced blood glucose after 45 minutes would suggest improvements in skeletal muscle 
glucose uptake and insulin signaling, as seen in animal heat stress models (Gupte et al., 
2009). 
There are multiple potential mechanisms for the observed changes in whole-body 
and adipose tissue-specific changes in glucose tolerance and insulin sensitivity. As stated 
above, the increase in Hsp27 and decrease in IKKβ observed in adipose tissue is likely in 
part responsible for enhanced insulin signaling in adipocytes. While adipose tissue plays 
a small role in whole-body glucose uptake, insulin’s role in suppressing hormone-
sensitive lipase can impact insulin sensitivity and glucose uptake in other tissues, as 
enhanced suppression of lipolysis in HT subjects would reduce fatty acid accumulation in 
liver and skeletal muscle. Since this lipid accumulation is involved in obesity-induced 
systemic inflammation and insulin resistance, future work examining changes in insulin 
sensitivity, glucose uptake, HSP, and inflammatory protein abundance in skeletal muscle 
biopsies can elucidate the impact of heat therapy on other tissues. In addition, heat 
acclimation in human (Brunt et al., 2016a) and animal models (Maloyan et al., 2005) 
increased angiogenic signals, which could impact blood supply to adipose tissue and 
therefore reduce the hypoxia and inflammation associated with hypertrophic adipocytes. 
The women in this study also experienced a decrease in sympathetic outflow, serum 
testosterone, and circulating inflammatory cytokines (see Chapter V), which can impact 
adipose tissue function by catecholamine-induced fatty acid release, promotion of 
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adipocyte hypertrophy, and promotion of intracellular inflammation, respectively. 
Finally, repeated heat shock in mice induced increases in serum adiponectin (Morera et 
al., 2012), an adipokine highly associated with insulin sensitivity (Díez & Iglesias, 2003; 
Albers et al., 2015b). As adiponectin is decreased in obese women with PCOS (Spritzer 
et al., 2015), this may exacerbate insulin resistance (Villa & Pratley, 2011) and a possible 
increase in circulating adiponectin could contribute to the observed systemic 
improvements in this study. 
In summary, repeated heat exposure improved whole-body glucose uptake, 
systemic insulin sensitivity, and insulin signaling in subcutaneous adipose tissue in obese 
women with PCOS. These improvements may be related to increased Hsp27 abundance 
and reduced IKKβ abundance in subcutaneous adipose tissue, but given the global and 
multifaceted stimulus of heat therapy, future work should examine the contribution of 
other potential underpinnings in these profound improvements including changes in 
visceral fat, liver, and skeletal muscle insulin signaling, potential adipose tissue 
angiogenesis, as well as circulating catecholamines and adipokines. 
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CHAPTER VII 
SUMMARY & FUTURE DIRECTIONS 
 
Heat has been used in various cultures for centuries with purported physiological 
and psychological benefit. However, until recently these potential physiological benefits 
were relatively unexplored in scientific literature. The pioneering work by Michal 
Horowitz using long-term (30 day) passive heat acclimation in animal models to examine 
systemic and cellular adaptations to heat exposure (Horowitz & Meiri, 1993; Maloyan et 
al., 2005; Horowitz & Assadi, 2010) brought forth many new avenues to explore in 
humans, including the potential for heat acclimation to improve cardiovascular and 
metabolic health. However, long-term passive heat interventions in humans with 
impaired cardiometabolic health have been limited, with indications of improved 
cardiovascular (Kihara et al., 2002) and metabolic (Hooper, 1992) health in heart failure 
and diabetes, respectively. 
This study builds upon previous work examining heat therapy by assessing 
changes in cardiometabolic health in women with PCOS, a population that serves as ‘a 
paradigm from prehypertension, prediabetes, and preobesity’ (Luque-Ramírez & 
Escobar-Morreale, 2014). While PCOS is a complex and multifaceted syndrome with a 
spectrum of dysfunction, the cardiometabolic health impairments in obese young women 
with PCOS create an ideal model to examine the impact of heat therapy in an at-risk 
population before long-term damage occurs due to hypertension, diabetes, or other 
complications.  
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The primary findings in Chapter IV include reduced arterial wall thickness, 
improved arterial compliance, enhanced endothelial function, reduced C-reactive protein, 
and increased tolerance to IR injury, which together create a profile of profound 
cardiovascular risk reduction in obese women with PCOS. While the magnitude of 
changes in some variables (FMD, arterial stiffness) was smaller than observed in healthy, 
inactive humans, other health markers (blood pressure, wall thickness, inflammation) 
exhibited larger improvements than seen in healthy humans (Brunt et al., 2016c). The 
large decrease in blood pressure in this pre-hypertensive population is particularly 
promising as an indication that heat therapy could be added to a lifestyle treatment in 
individuals with elevated blood pressure.  
The large reduction in MSNA observed over the course of heat therapy (Chapter 
V) may be in part responsible for the decrease in blood pressure, but changes in MSNA 
have bearing beyond blood pressure regulation in obesity and PCOS. Elevated MSNA 
can contribute to adipose tissue dysfunction in obesity (Smith & Minson, 2012), and 
elevated sympathetic activity to the ovary may play a role in ovarian dysfunction and 
androgen production in PCOS (Lara et al., 1993, 2005). The change in serum testosterone 
and the reports from multiple subjects that they resumed regular menstrual cycles are 
perhaps the most novel and exciting findings in this study, as they go beyond 
cardiometabolic risk reduction and potentially impact the pathogenesis of PCOS. 
Insulin resistance also serves an important role in PCOS pathogenesis (Dunaif et 
al., 1992, 2001; Dunaif, 2017) and can contribute to excess androgen production and 
elevated sympathetic outflow. Therefore, the change in adipocyte and whole-body insulin 
resistance over the course of heat therapy (Chapter VI) not only altered metabolic health, 
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but may have additionally contributed to decreased androgen production, decreased 
markers of inflammation, and restoration of eumenorrhea in some HT subjects. However, 
given that fasting insulin did not change over the course of heat therapy, it is unlikely that 
changes in insulin contributed to changes in baseline MSNA. In applying heat therapy to 
insulin-resistant populations beyond women with PCOS, the changes in glucose uptake, 
HOMA-IR, insulin AUC, and adipocyte insulin signaling observed in this study show 
great promise for pre-diabetic or type 2 diabetic individuals as an adjunctive therapy to 
reduce hyperglycemia as seen in Hooper & Hooper’s early work (Hooper, 1992). This 
study builds on their work by implementing a longer heat intervention, observing glucose 
and insulin responses to an OGTT, and examining adipose tissue markers of insulin 
signaling and inflammation in order to examine potential mechanisms behind the 
observed decrease in blood glucose seen with hot tub use in type 2 diabetics. 
The decreased markers of inflammation in subcutaneous adipose tissue (IKKβ) 
and in circulation (C-reactive protein, TNFα) are related to most cardiometabolic health 
outcomes, as meta-inflammation plays an important role in vascular health, sympathetic 
activity, and insulin resistance.  It is possible that changes in HSP expression or 
abundance over time in various tissues are mediating these changes in inflammation; 
however; we only observed an increase in Hsp27 abundance after heat therapy in 
subcutaneous adipose tissue. The limited timepoints (Pre-Post) and tissue (subcutaneous 
adipose tissue) that we were able to observe did not allow for examination of a 
timecourse or tissue-specific effect. Considering that HSP abundance can be up-regulated 
in response to response to hypoxia or reactive oxygen species (Kregel, 2002), it is 
possible that an improvement in adipose tissue perfusion or oxidative stress over time 
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blunted a possible heat-mediated increase in HSP expression as seen in animal heat stress 
(Gupte et al., 2009; Rogers et al., 2015) or heat acclimation models (Horowitz & Assadi, 
2010). 
Implications and Future Directions. The overarching implication of these findings 
is that heat therapy is an extremely promising intervention that leads to robust 
improvements in cardiovascular and metabolic health in obese women with PCOS. While 
it appears that changes in HSP abundance, adipose tissue and systemic inflammation, and 
sympathetic activity are driving changes in this population, it remains difficult to tease 
apart the underlying mechanisms or relative influence of each component. We 
endeavored to examine mechanisms behind the observed improvements in 
cardiometabolic health with heat therapy; however; the reductions in inflammation, 
sympathetic nerve activity, and serum androgens are likely a small piece of the cellular 
and systemic adaptations that occur over heat therapy. For example, in animal work, 
changes in protein expression (Maloyan et al., 2005; Horowitz & Assadi, 2010), hormone 
or neurotransmitter receptor density (Umschweif et al., 2014) , epigenetic modification 
(Horowitz, 2007, 2014), and tissue-specific protein abundance (Gupte et al., 2009; 
Rogers et al., 2015) all occur with long-term heat exposure and likely play an important 
role in health outcomes. Future research examining these mechanisms in humans can 
further characterize the cellular and systemic changes that occur with heat therapy in 
health and disease. 
The other large remaining gaps in current research are the time course of 
induction and decay of heat therapy benefits, the ‘dose’ (time x temperature) of heat 
needed to see these benefits, and the stimulus required to maintain benefits after an 8-10 
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week heat therapy intervention. We can clearly see from the current study and previous 
work using hot water immersion (Brunt et al., 2016c) that most changes take the full 8-10 
weeks (30-36 heat sessions) to manifest both in healthy individuals and in those with 
impaired cardiometabolic function. However, we do not know how long these changes 
persist after heat therapy, and whether it is possible to maintain them over time with 
regular heat doses after the initial induction. Based on Horowitz’s work on epigenetic 
modification and cytoprotective memory in heat acclimation (Horowitz, 2014), it is 
possible that benefits could be maintained or even expanded with a less frequent heat 
stimulus after the initial intervention. 
Heat therapy research in humans is still in its infancy, and future directions in 
diseased populations, optimal intervention timelines, and underlying mechanisms have 
important implications in human health through a spectrum of disease states. This study 
examining heat therapy in obese women with PCOS provides a glimpse of the myriad 
cardiovascular, autonomic, and metabolic benefits of heat therapy, and many potential 
avenues for further exploration. 
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